Mieloma m?ltiple - Gu?a para el paciente
Edici?n 2011/2012
IMF DNA BANK IDENTIFIES GENETIC VARIATIONS RELATED TO PREDISPOSITION TO MM AND RESPONSE TO TX
LIGHTS, CAMERA, CURE! The IMF's 15th Anniversary Gala a Winner!
1070
Blood Drive dedicated to IMFer Michael Tuohy
The Role Of The Ras Oncogene In Multiple Myeloma Spread
Long-Term Survivorship Guidelines for Multiple Myeloma Patients
Welcome and Introduction by Beth Faiman, MSN, APRIN-BC, AOCN

What is a Transplant?
IMF 5th Annual Comedy Celebration
benefiting the Peter Boyle Memorial Fund
Difference Made in New York by Nurse Leadership Board Member
An interview with Nurse Leadership Board member Bonnie Jenkins, RN
Understanding Protein Electrophoresis
Step 1: MGUS
Myeloma Minute - January 18, 2006
Autologous Bone Marrow and Stem Cell Transplantation For Multiple Myeloma, part 2
SZPICZAK MNOGI PORADNIK DLA PACJENT?W
Myeloma Minute - October 25, 2007
Guida Per Il Paziente
Introduction to Proteasome Inhibition
Overview of the Cancer Patient Statement of Principles
THE INTERNATIONAL MYELOMA FOUNDATION CONGRATULATES FRIEND AND COLLABORATOR DR. LUC MONTAGNIER FOR BEING AWARDED THE NOBEL PRIZE
IMF Multiple Myeloma Patient Handbook 2010/2011
Overview of ASH 2010
ASH 2010 Overview from Dr. Vincent Rajkumar
Entendendo a Terapia com VELCADE?
VELCADE^® (Bortezomib) verstehen
Conociendo VELCADE® (bortezomib) para inyección
IMF Sponsors Symposium Preceding 46th Annual ASH Meeting
Hastalara y?nelik ek kitabı
BANK ON A CURE® "GENE BANK" RESEARCHERS IDENTIFY PATHWAYS THAT MEDIATE SIDE EFFECTS FROM WIDELY-USED MYELOMA TREATMENT
INTERNATIONAL MYELOMA FOUNDATION (IMF): STUDI MULTIPLI PRESENTATI IN OCCASIONE DELLA CONFERENZA MONDIALE SUL CANCRO INDICANO NUOVE TERAPIE CHE CAMBIANO LA PROSPETTIVA PER I PAZIENTI AFFETTI DA NEOPLASIE EMATOLOGICHE
INTERNATIONALE MYELOMSTIFTUNG: MEHRERE STUDIEN AUF GLOBALER KREBSKONFERENZ ZEIGEN DIE VERBESSERUNG DER AUSSICHTEN FÜR BLUTKREBSPATIENTEN DURCH NEUE THERAPIEN
THE INTERNATIONAL MYELOMA FOUNDATION: MULTIPLE STUDIES AT GLOBAL CANCER CONFERENCE SHOW NEW THERAPIES CHANGING THE OUTLOOK FOR PATIENTS WITH BLOOD CANCERS

LA FONDATION INTERNATIONALE DU MYÉLOME: DES ÉTUDES MULTIPLES PRÉSENTÉES À LA CONFÉRENCE MONDIALE DE CANCÉROLOGIE INDIQUENT QUE LES NOUVELLES THÉRAPIES CHANGENT LE PRONOSTIC DES PATIENTS ATTEINTS DE CANCER DU SANG

LA FUNDACIÓN INTERNACIONAL DEL MIELOMA: MÚLTIPLES ESTUDIOS EN LA CONFERENCIA MUNDIAL DEL CÁNCER DEMUESTRAN QUE LAS NUEVAS TERAPIAS ESTÁN CAMBIANDO EL PRONÓSTICO DE PACIENTES CON CÁNCER DE SANGRE

February 13, 2004 Myeloma Minute
Excerpts from Acceptance Speeches at Cirque de la Vie
What's New In Research - February 12, 2004
Applying For An International Myeloma Foundation Research Grant
EMEA Marketing Approval of REVLIMID® is Important Advance for Patients in Europe
14th Anniversary Ribbon of Hope Gala Honorees:
QUALITY OF LIFE AWARD
IMF 2001 Research Grant Awards
IMF 2000 Research Grant Awards
The Role Of Osteoclast Differentiation Factor TRANCE in Myeloma-Associated Bone Destruction
IMF 1999 Research Grant Awards
Immune-Mediated Clearance Of AL-Amyloid
Dendiric Cell-Based Vaccination With Idiotype For Amyloidosis And Post-Transplant Myeloma
Isolation Of Myeloma-Cytotoxic T Lymphocytes - Identification of Myeloma Tumor Antigents
Targeted Radioimmunotherapy For The Treatment Of Myeloma: A Preliminary Pharmacodynamic Study
1998 IMF Research Grant Awards
Kaposi's Sarcoma-Associated Herpesvirus Cytokines in the Oncogenesis of Multiple Myeloma
Characterization of 14q32 Translocations In Multiple Myeloma
Moncolonal Antibody Directed Immunotherapy For The Treatment Of Multiple Myeloma
Molecular Mechanisms Of Myeloma Cell Resistance To Apoptosis
1997 IMF Research Grant Awards
IMF 1996 Research Grant Award
IMF 1995 Research Grant Award
IMF to Establish European Base of Operations in Germany
Myeloma Minute - December 7, 2005
FDA Approves Aredia For The Treatment Of Myeloma Bone Disease
Important New Blood Cancer Initiative Announced on Capital Hill
What's New In Research - May 23, 2003
The Unknown Patient Reports from the IXth International Myeloma Workshop
IXth International Myeloma Workshop - Thursday, May 22nd, 2003
Complementary and Alternative Medicine
Richie Test
Barisa's Test
The Page You Requested Is Not Available
多発性骨髄腫
患者の手引き
СПРАВОЧНИК ПАЦИЕНТА
Множественная Миелома
Рак Костного Мозга
Patientenhandbuch
Robert A. Kyle, MD
Forming A Myeloma Support Group
June Brazil in Memoriam
Upcoming Professional Meetings
Forming A Support Group - Sample Flyer
Sample Support Group Newsletter
June, 2001 Senate Hearing on Blood Cancer Research: A personal photo journal
Senate hearing on Blood Cancer Research
LE MY?LOME MULTIPLE - GUIDE DU PATIENT
MIELOMA M?LTIPLO - MANUAL DO PACIENTE
Hand Printed Christmas Cards
Myeloma Minute - November 13, 2007
The new site
The use of VELCADE® in a frontline setting.
Introduction
Oncogenic Events
The Malignant Clone In Myeloma
Innovative Technologies
Signaling and Microenvironment
Angiogenesis In Multiple Myeloma
Treatment Modalities and Symptom Management
Bone Metabolism, Bone Disease, and the Bisphosphonates
Allogeneic and Autologous Transplantation
Thalidomide: Clinical Outcomes
Vaccine Strategies in Multiple Myeloma
Immunotherapies and Control Of Residual Disease
New Therapies
Helen Bos
A Brief History of the IMF
Comprensione Revlimid®
Multiples Myelom Handbuch Zur Erkrankung Und Behandlung
January 3, 2002: IMF Myeloma Minute

RESPONSE ASSESSMENT: IS TREATMENT WORKING?"></A><br>
<A href="3474.html"><img src="http://myeloma.org/images/steps/10-Steps_Step07.jpg" width="644" height="125" alt="CONSOLIDATION AND MAINTENANCE"></A><br>
<A href="3475.html"><img src="http://myeloma.org/images/steps/10-Steps_Step08.jpg" width="644" height="125" alt="MONITORING WITHOUT MYSTERY"></A><br>
<A href="3476.html">Living Well with Myeloma 2011 ? Drug Interactions and Contra-Indications.</A><br>
<A href="3478.html">Thursday! Advocacy Training Webinar for the Cancer Coverage Parity Act of 2011. Learn how YOU can make a difference!</A><br>
<A href="3479.html">Summary of the Second Annual International Myeloma Working Group Summit<br>London June 7-9 2011</A><br>
<A href="3480.html">Gala 2011 Committee</A><br>
<A href="3481.html">Gala 2011 Event Sponsors</A><br>
<A href="3482.html">Gala 2011 Tickets</A><br>
<A href="3483.html">Gala 2011 Advertising & Sponsorship Opportunities</A><br>
<A href="3484.html">Gala 2011 Press and Media</A><br>
<A href="2873.html">Advocacy Update - January 15, 2010</A><br>
<A href="1284.html">Senators Urge Medicare to Cover PET Scans for Myeloma Patients</A><br>
<A href="343.html">Edmundo Gorga</A><br>
<A href="253.html">Bart Barlogie, M.D., Ph.D.</A><br>
<A href="254.html">Raymond Alexanian, M.D.</A><br>
<A href="255.html">Alan Solomon, MD</A><br>
<A href="256.html">Kenneth C. Anderson, M.D.</A><br>
<A href="1629.html">Myeloma Minute - October 4, 2005</A><br>
<A href="257.html">Giuseppe Avvisati, MD</A><br>
<A href="258.html">Jean-Luc Harousseau</A><br>
<A href="259.html">Regis Battaile, MD</A><br>
<A href="261.html">Daniel R. Bergsagel, MD</A><br>
<A href="262.html">Joan Blad?, M.D</A><br>
<A href="263.html">Mario Boccadoro, MD</A><br>
<A href="264.html">Y.C. Chen, MD</A><br>
<A href="265.html">J. Anthony Child, MD</A><br>
<A href="266.html">Meletios-Athanassios Dimopoulos, MD</A><br>
<A href="267.html">Brian G.M. Durie, MD</A><br>
<A href="268.html">G?sta Gahrton, MD</A><br>
<A href="269.html">Dr. Vania Hungria</A><br>
<A href="270.html">Douglas Edward Joshua, MD</A><br>
<A href="271.html">Tadamitsu Kishimoto, MD, Ph.D.</A><br>
<A href="272.html">Heinz Ludwig, MD</A><br>
<A href="273.html">James S. Malpas, MD</A><br>
<A href="274.html">H?ken Mellstedt, M.D., Ph.D.</A><br>
<A href="275.html">Angelina Rodriguez Morales, MD</A><br>
<A href="276.html">Dorotea Fantl, MD</A><br>
<A href="277.html">Ian Franklin, MD</A><br>
<A href="278.html"><b>Gregory R. Mundy, MD<br>Professor of Medicine – Endocrinologist</b></A><br>
<A href="279.html">Martin Oken, MD</A><br>
<A href="280.html">Linda Pilarski, MD</A><br>
<A href="281.html">Ray Powles, MD</A><br>
<A href="282.html">Pieter Sonneveld, MD</A><br>
<A href="283.html">Benjamin Van Camp, MD Ph.D.</A><br>
<A href="284.html">LLM ACT: Leukemia, Lymphoma and Myeloma: Action, Communication, Teamwork</A><br>
<A href="285.html">National Cancer Institute Leukemia, Lymphoma And Myeloma Progress Review Group (PRG)</A><br>
<A href="286.html">Access to Cancer Therapies Act, H.R. 1624 / S. 913, Medicare Coverage of Anti-Cancer Therapies</A><br>
<A href="287.html">Access to Cancer Clinical Trials Act H.R. 967</A><br>
<A href="288.html">Department of Defense Research Program Success of Cancer Research Initiatives at DoD</A><br>
<A href="289.html">IMF 11th Anniversary Gala</A><br>
<A href="290.html">Thank You to the Sponsors of the IMF Website!</A><br>
<A href="291.html">Anonymous #1</A><br>
<A href="292.html">Bill Bauknecht</A><br>
<A href="293.html">Nancy Bengston</A><br>
<A href="294.html"><strong>Submit a Myeloma Survivor Story</strong></A><br>
<A href="295.html">Don Biddison</A><br>
<A href="297.html">What is an autologous stem cell transplant and am I a candidate for one?</A><br>
<A href="298.html">What is an M spike and is it different from the M Protein?</A><br>
<A href="299.html">What is nonsecretory myeloma?</A><br>
<A href="437.html">Myeloma Minute</A><br>
<A href="308.html">耐心的手册</A><br>
<A href="332.html">A Guide to Creative Giving</A><br>
<A href="337.html">Peter Coulthurst</A><br>
<A href="695.html">What

KOS 2007: International Staging System for Multiple Myeloma

KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
International Myeloma Foundation Supports Senator Hutchison Initiative
Greetings from Australia
Pictures from the Philadelphia Patient and Family Seminar - October 17-18, 2003
Myeloma Minute - July 27, 2004
14th Anniversary Ribbon of Hope Gala Honorees
14th Anniversary Ribbon of Hope Gala Sponsors
14th Anniversary Ribbon of Hope Gala Honorees:
COURAGE AWARD
14th Anniversary Ribbon of Hope Gala Honorees:
GUEST OF HONOR
14th Anniversary Ribbon of Hope Gala Honorees:
VISIONARY AWARD
Pictures from the San Jose Patient and Family Seminar
July 16-17, 2004
Medicare eligible? Apply NOW to save 90% of thalidomide costs!
Myeloma Minute - August 2, 2004
Myeloma Minute - July 27, 2004
Third Annual Myeloma Awareness Week (August 20 -30)
IMF Raises Awareness of little known Cancer
Michio M. Kawano, MD
QUARTERLY UPDATE FROM BANK ON A CURE?
February 2004
IMPORTANT INFORMATION ABOUT THE MEDICARE DEMONSTRATION PROGRAM
QUARTERLY UPDATE FROM BANK ON A CURE?
Summer 2004
First Myeloma-Specific Cancer Patient DNA Bank Becomes a Reality
Special Myeloma Minute: Medicare eligible? Apply NOW to save 90% of thalidomide costs!
Myeloma Minute - August 18, 2004
I'm Not Leavin'
by Michael Tuohy
IMF Welcomes Multiple Myeloma Research Consortium to Team
The IMF at Work in Washington
IMF Urges Medicare to Add Thalidomide to Demonstration Project
IMF Receives Million Dollar Grant from Centers for Disease Control and Prevention
14th Anniversary Ribbon of Hope Gala Auction
14th Anniversary Ribbon of Hope Gala Auction - Travel
14th Anniversary Ribbon of Hope Gala Auction - Entertainment
Applications to Medicare Demonstration Project Far Below Expectations
CMS May Limit Off-Label Coverage For Cancer Drugs To Clinical Trials
The IMF Presents the 2nd Annual Myeloma Awareness Week
Myeloma Minute - September 30, 2004
International Myeloma Foundation Privacy Statement
Guide to Drug Names
IMF WALL OF MIRACLES
A Comprehensive Guide to Torino Multiple Myeloma 2004 Conference
Myeloma Minute - October 17, 2004
Jayesh Mehta, MD
What would be the significance of FDA Approval of Thalidomide for Myeloma?
Myeloma Minute - October 26, 2004
IMF Holiday Cards
The Benefits of Adding Thalidomide to a DVd Regimen
REPORT FROM THE 14th ANNIVERSARY RIBBON OF HOPE GALA
San Diego Patient & Family Seminar a Sold Out Success
14th Anniversary Ribbon of Hope Gala Honorees:
RIBBON OF HOPE AWARD
IMF "Ask the Expert" Video: Donna Weber, MD
M.D. Anderson, Houston, TX
CITINGS
ASH 2004 Webcast
Myeloma Minute - December 3, 2004
YOUR IMF DOLLARS AT WORK
CURRENT U.S. EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT
OVERVIEW OF KYPHOPLASTY IN THE MANAGEMENT OF SPINAL TUMORS
APEX
PAD COMBINATION THERAPY FOR PREVIOUSLY UNTREATED PATIENTS
EVALUATION OF THE PATIENT IN INITIAL RELAPSE AND SELECTION OF SECOND-LINE THERAPEUTIC OPTIONS
OSTEONECROSIS OF THE JAWS IN MYELOMA:
Time Dependent Correlation with AREDIA and ZOMETA Use
NEW APPROACHES TO MYELOMA STAGING AND FRONT-LINE TREATMENT SELECTION
New, Improved Staging System for Multiple Myeloma Developed for Use Around the World
PRELIMINARY CASE EVALUATION: AN INTERACTIVE ASSESSMENT OF AUDIENCE TREATMENT OPTIONS
SUPPORTIVE CARE AND THE MANAGEMENT OF THE NEWLY DIAGNOSED AND INITIALLY RELAPSING PATIENT
CURRENT EUROPEAN EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT
CONTROVERSIES IN MYELOMA MANAGEMENT
Diagnosis, Initial Treatment and the Relapsing Patient
Primary Treatment with Pulsed MDT in Symptomatic Elderly Patients
Pilot Study Evaluating the Safety & Efficacy of AMD3100 ...
Randomized Trial Comparing MP, MP-THAL and MEL100 for Newly Diagnosed Pts Aged 65-75 Years
ECOG Clinical Trials in Myeloma For Newly-Diagnosed Patients
Fonseca
Antibody-Based Therapy Targeting Myeloma Stem Cells
A Phase I, Multi-Dose Study of SGN-40 (anti-huCD40 mAb) in Patients with MM
Bortezomib as First-Line Therapy in Patients with MM; A Multicenter Phase 2 Clinical Trial
DEVELOPMENT, PREDICTION, AND TREATMENT OF ANEMIA IN PATIENTS WITH LYMPHOMA/MM
Depsipeptide in the Treatment of Relapsed and Refractory MM: A Prospective Evaluation
MPT vs MP: INTERIM ANALYSIS PROSPECTIVE RANDOMIZED TRIAL NEWLY DIAGNOSED PATIENTS AGE > 65 YEARS
A Randomized Phase III Trial of Thal/Dex vs Dex in Newly Diagnosed MM (E1A00)
Phase 2 Trial of Single Agent Bortezomib in Patients with Previously Untreated Multiple Myeloma
Bortezomib Vs High-Dose Dexamethasone in Relapsed MM: Results of a Large Randomized Phase 3 Study
Phase I/II Nat'l Open-label Study of Bortezomib + Melphalan + Prednisone in Elderly Untreated MM Pts
Poorer Survival in Multiple Myeloma Correlates with Patients? Age...
THAL + DEX IS EFFECTIVE SALVAGE REGIMEN FOR PTS RELAPSING AFTER AUTOLOGOUS TRANSPLANT
Siegel
Sundar Jagannath, MD
VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.
Rodriguez ASH
[4869] IL-101082-A and TNF-Alpha 238/308A Genotypes Associated with Earlier (< 55) Onset of MM
REPORT FROM THE IMF- AND ICHE-SPONSORED
CONTROVERSIES IN MYELOMA MANAGEMENT
Clin. implications of t(11;14)(q13;q32), t(4;14)(p16;q32) and -17p13 (p53) deletions in pts with HDT
IMFer Michael Katz Receives Certificate of Appreciation from National Cancer Institute
CASE EVALUATION REVISITED
International Myeloma Foundation (IMF) to Bring Highlights from Prestigious International Myeloma Wo
Message from IMF President
Why Bank On A Cure??
Treating Multiple Myeloma: The Little Rock Approach
The Genetics of Multiple Myeloma
Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the Proteasome
Education Initiative
Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma
Cancer Research and Medicare: Political Pork?
IMF Kicks Off 2004 Seminars with Florida Retreat
Los Angeles Area Support Group Salutes Leader
IMFers Pay Tribute To Janet Johnson
International Myeloma Foundation Celebrates Landmark Success of 2004
One Voice Against Cancer
Letter to President Bush
One Voice Against Cancer Lobby Day
Spotlight on The Myeloma Foundation of Australia
Federal Cancer Policy: The Big Picture and its Consequences
The IMF Latin America
Myeloma Minute - February 10, 2005
Download the classic folksong Shenandoah to your iPod or Zune, and make a donation to the the IMF.
Did You Know?
The Gift of Good Nutrition
Ask the Expert: Thalidomide and the ImiDs
Research Progress Report: Dr. Ivan Van Riet
YOUR GIFTS AT WORK: 2003 Brian D. Novis Research Grant Awards
News & Notes
My New First Birthday
IMF Receives Four-Star Rating from America's Largest Charity Evaluator
Man raises awareness of myeloma: Profile of Peter Tischler
Myeloma Minute - March 20, 2005
Dallas 2005 Patient & Family Seminar
Myeloma Minute - Coming to a City Near You!
Charity Navigator Gives IMF Highest Rating Available
IMFers Share Their Thoughts
Patient Perspective: Tracking My Numbers
Patient Perspective: My New First Birthday
Message from the IMF President
ASH 2004: The Avalanche of Information Continues
New Developments in Multiple Myeloma
The Expanding Role of Proteasome Inhibition in Multiple Myeloma
IMFer Profile: Andy Lebkuecher
Meet the New IMF Director of Support Groups
Wnt/ß-catenin Signaling in Multiple Myeloma
IMF NAMES 2010 ROBERT A. KYLE LIFETIME ACHIEVEMENT AWARD RECIPIENT PROF. JOAN BLADÉ
Advocacy Update - February 15, 2010
March is Myeloma Awareness Month!
A Patient Advocacy Coalition Led by the International Myeloma Foundation and the MDS Foundation Says Its Cancer Patient Statement of Principles Gains Momentum Going into the ASH Cancer Conference
Paris 2009 S?minaire - Evolution de la prise en charge du sujet jeune
Paris 2009 S?minaire - Traitement de première ligne du myélome multiple chez les patients non éligibles au traitement intensif avec autogreff de CSH
Paris 2009 S?minaire - Allogreff de cellules souches hématopoïétiques
Paris 2009 S?minaire - Introduction & Myeloma 101
Paris 2009 S?minaire - Questions et Réponses
Multiples Myelom - Grundbegriffe
Selbsthilfe und ihre Bedeutung
Malen als Therapie
Neue Klassifikationen des Multiplen Myeloms - Welche Relevanz haben sie für den Patienten?
Bildgebung beim Multiplen Myelom
"MRT/CT/Röntgen - wann indiziert?"
Progress in Treating Multiple Myeloma
Neue Substanzen: Zukunftsperspektiven in der Therapie des Multiplen Myeloms
Onkologische Nachsorge
Psychologische Betreuung für Patienten & Angehörige
Bisphophonate
Ballon Kyphoplastie
Knochenmarkdiagnostik
muß dies sein
Neue Substanzen in der Therapie des Multiplen Myeloms
Multiples Myelom: Wann behandeln? Wie kontrollieren?
Introduction and Bone Disease in Myeloma
La Terapia
La Terapia
La Terapia
Discussione - 1
La terapia del paziente giovane
La terapia del paziente giovane
Problemi legati alla terapia
Problemi legati alla terapia
Discussione - 2
Cos'è un protocollo clinico - rispondono data managers and research nurses
Il Consenso Informato
Il Ruolo dell'Infermiere in un D.H. di Ematologia: Procedura per Infusione Bortezomib
Discussione - 3
International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma¹
North Texas MM Support Group
Myeloma Minute Special Edition: Important VELCADE® News
Katie's Birthday
The Touching Story of a Little Girl's Love
Sydney 2005:
Welcome
Sydney 2005:
Unconventional Switched Bone Marrow Plasma Cells with Ig V-region Mutations
Sydney 2005:
Cell Cycle Control of Multiple Myeloma Pathogenesis
Sydney 2005:
Cross-talks Between Plasma Cells and the Microenvironment: Triggering and Targeting
Sydney 2005:
Immunophenotype of the Malignant Clone ? Implications on Management
Sydney 2005:
Clinical and Biologic Implications of Genomics in Myeloma
Sydney 2005:Pathogenic Events Identified by Chromo. Translocations & Cyclin D Exp. Determine Myeloma
Sydney 2005:
Pathogenesis of Myeloma: Ig Translocations, Cyclin D Dysregulation, Other Events
Sydney 2005:
Epigenetic Changes in the Molecular Pathology of Multiple Myeloma
Sydney 2005:
Alternative Gene Splicing in Myeloma; Aberrant Splicing of Hyalur.
Sydney 2005:
Is Thalidomide First Line Therapy?
Sydney 2005:
Thalidomide and Cardiovascular Complications in MM
Sydney 2005: Opening Ceremonies
Sydney 2005:
New Advances in the Management of Myeloma Bone Disease
Sydney 2005:
Plasmapheresis in Renal Failure
Sydney 2005:
Prevalence, Pathogenesis & Treatment of Anemia with Erythropoetic Agents in MM
Sydney 2005:
Epidemiology of Multiple Myeloma
Sydney 2005:
Smoldering MM: Criteria for Diagnosis & Results of Long-Term Follow-Up
Sydney 2005:
The Evolving vs Non-Evolving Nature of Asymptomatic Monoclonal Gammopathies
Sydney 2005:
The International Staging System for Myeloma: An Update
Sydney 2005:
Advances in Diagnosis and Imaging in MM
Sydney 2005:
Normal Plasma Cell Development and Pathogenesis of MGUS and MM
Sydney 2005:
Cell. Model for MM Cell Growth & Differentiation Based on Intra-clonal CD45 Microenv
Sydney 2005:
Intercellulalar Communication Signals Determined by Gene Expression Profiling in MM
Sydney 2005:
The Funcation and Movement of CD45 Molecule in IL6-induced MM Cell Expression
Sydney 2005:
Maintenance Therapy After Autologous Stem Cell Transplantation: IFM99 Trial
Sydney 2005:
What Have the Transplant Registries Taught Us?
Sydney 2005:
HDT Options for Elderly Myeloma Patients: Results of a Randomized Controlled Trial
Sydney 2005:
Total Therapy for Newly Diagnosed MM: the Arkansas Experience
Sydney 2005:
Is Double Autograft the Standard of Care?
Sydney 2005:
Pathogenesis of Myeloma Bone Disease
Sydney 2005:
Osteoblast Function in Myeloma (endothelin 1, osteoblast proteosome)
Sydney 2005:
Bisphosphonates and the Bone Microenvironment
Sydney 2005:
Mouse Model in Tumour Microenvironment and Bone Disease
Sydney 2005:
Lenalidomide (CC-5013, Revlimid?) and Other IMiDs
Sydney 2005: Pegylated Doxorubicin in Combination w Immune-modulators & Arsenic
Sydney 2005:
Overview of New Therapies and Future Directions
Sydney 2005:
The Influence of the Tumour Microenvironment on Drug Response & Drug Resistence
Sydney 2005:
Angiogenesis in Myeloma - An Overview
Sydney 2005:
New Antiangiogenic Agents
Sydney 2005: Targeting of VEGF and PDGF Signaling by Receptor Tyrosine Kinase Inhibitors Impairs...
Sydney 2005: Molecular Mechanism Involved in Homing and Migration of Plasma Cells to the Bone Marrow
Sydney 2005:
Mechanisms of Oncogenesis in Waldenstrom's Macroglobulinemia
Sydney 2005:
Novel Insights into the Biology & Therapy of Waldenstrom's Macuglobulinemia
Sydney 2005:
Treatment of Waldenstrom's Macroglobulinemia
Sydney 2005:
Amyloidosis
Sydney 2005: Cryoglobulinaemia, POEMS and Gammopathy Associated Neuropathy
Professor Jean-Luc Harousseau Receives Prestigious Waldenstrom Award for a Lifetime of Achievement
Daily Update from International Myeloma Workshop - April 11, 2005
Myeloma Minute - February 28, 2006
Sydney 2005: In MM 14q32 Transloc. are Present in Memory B Cells but RAS Mutations are Restricted...
Daily Update from International Myeloma Workshop - April 12, 2005
Daily Update from International Myeloma Workshop - April 13, 2005
Daily Update from International Myeloma Workshop - April 14, 2005
Sydney 2005: The Transcriptome of MM Defines Disease Subgrps w/ Distinct Genetic & Clinical Features
Sydney 2005:
Translocation (4:14), Fibroblast Growth Factor Receptor 3 (FGFR3) and MM
Sydney 2005:
The Pharmacogenomics of Myeloma
Sydney 2005: Associations of Genetic Variation with Clinical Outcome: Update on Bank On A Cure
Sydney 2005: Microarray Exp. Profiling Indicates Upreg. of Ribosomal Machinery in del(13)-Neg Clone
Sydney 2005: Intensive v Double Intensive Tx in Untreated MM: Update of HOVON 24 MM
Sydney 2005: Single v Double HDT in MM: Second Analysis of the Trial GMMG-HD2
Sydney 2005: HDT / Stem Cell Support in MM: Update of the Spanish Studies (PETHEMA/GEM)
Sydney 2005: Double v Single ASCT & Role of Added Thal as First-line Tx for MM (Bologna 96 and 02)
Sydney 2005:
Update on High Dose Therapy: MAG Studies
Sydney 2005:
Update on High Dose Therapy: MRC Studies
Sydney 2005:
New Therapeutic Approaches in Myeloma Bone Disease
Sydney 2005: MIP-1a: Osteolytic & Tumour-Promoting Effects in MM Bone Disease
Sydney 2005:
RANK and MIP-1alpha in MM: Clinical Implications
Sydney 2005: Toward the Elucidation of the Role of Altered Wnt Signaling MM
Sydney 2005:
MIP-1 May Cause Reciprocal of Osteoclast and Dendritic Cell Diff. from Monocytes
Sydney 2005:
State of the Art of Allogenic Transplantation in MM
Sydney 2005:
What is the Role of Reduced Intensity Allogeneic Stem Cell Transplantation?
Sydney 2005:
High Dose or Reduced Intensity Conditioning for MM?
Sydney 2005: Strategies to Improve the Graft v MM Effect of Allo SCT & Donor Lymphocyte Infusions
Sydney 2005:
Efficacy of a 2nd Transplant with a 1st ASCTResults from a Spanish PETHEMA/GEM Study
Sydney 2005:
Bone Marrow Homing of MM Cell
Sydney 2005:
Role of the IGF-1/IGF-1 Receptor Pathway in the 5TMM Experimental Mouse Model
Sydney 2005:
AKT in MM: Therapeutic Implications
Sydney 2005: In MM Cells, Birn Pro-Apoptotic Functionis Neutralized Thru Endogenous Mcl-1/Birn ...
Sydney 2005: Inhibition of MM Cell Proliferation & Increase of Apoptosis thru Reg. of NF-kB & JNK...
Sydney 2005: Human Apurinic/Apyrimidinic Endonucleases (Ape1 & Ape 2) Leads to Genetic Instability
Sydney 2005: Bone Marrow Microvessel Endothelial Cells in MM Harbor MM-Assoc. Chromosomal Transloc.
Sydney 2005:
Coexpression of CD11a and CD45bright is the Hallmark of Proliferating Cell Malig.
Sydney 2005:
Bcl-xl, Myc, and Mutant Ras Transgenic Mouse Models of Plasma Cell Malignancies
Sydney 2005:
Final Results of IFM9904 Protocol: Dbl. Transplant +/- anti-IL6 Mono. Antibody in..
Sydney 2005: 1st Interim Analysis of Joint HOVON-GMMG-HD3 Randomised Study
Sydney 2005: Interim Analysis of the IFM 99-06 Trial on 350 Patients
Sydney 2005:
Tumor Immune Interactions in Myeloma
Sydney 2005:
T Cells in Myeloma: Lessons from a Murine Model
Sydney 2005:
Dendritic Cell Biology in Multiple Myeloma
Sydney 2005: Phenotypic and Functional Alterations of Gamma/Delta T Cells in Myeloma
Sydney 2005: The Role of Dendritic Cell Genotype in the Induction of T-Cell Responses...
Sydney 2005: A Phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAb) ...
Sydney 2005: Antagonist Anti-CD40 antibody CHIR-12.12 Causes Tumour Regr. & Prolongs Survival in MM
Sydney 2005: CHIR-258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Tx of t(4;14) MM
Sydney 2005: Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in MM Cells ...
Sydney 2005: In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase inhibitor, CYC202..
Sydney 2005: Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor
Sydney 2005: Combination of Tipifarnib & Bortezomib Results in Synergistic MM Cell death...
Sydney 2005: Cancer Vaccine Treatment and Antibody Therapy in MM
Sydney 2005: Tumour Lysate Dendritic Cell Vaccination in Multiple Myeloma
Sydney 2005: Tumor Antigen Immunization of Human Allotransplant Donors in Myeloma
Sydney 2005: DNA Vaccination Against Myeloma Post Autologous or Allogeneic Transplantation
Sydney 2005: Dendritic Cell-Based Vaccination and Beyond
Sydney 2005:
Drug Resistance in Multiple Myeloma
Sydney 2005: Anti-apoptotic Signalling in Multiple Myeloma Cells: Therapeutic Implications
Sydney 2005: Mechanisms of Drug Resistance Towards Thal and IMiDs in MM cells: role of C/EBPb
Sydney 2005: Lack of Mcl-1 Confers Resistance to Bortezomib and Melphalan but not Doxorubicin
Summary of the Xth International Myeloma Workshop
Myeloma Minute Special Edition: Updates from the International Myeloma Workshop in Sydney, Australia
IMF Presents Research Triple Play at Xth International Myeloma Workshop
Professor Jean-Luc Harousseau Receives Prestigious Waldenstrom Award
A Brief History of the International Myeloma Workshop
Update on Lenalidomide (CC-5013; Revlimid?)
Meet New Members of the IMF Scientific Advisory Board
Supportive Care: Erectile Dysfunction - Current Treatment Options
Report from the Atlanta 2005 Patient & Family Seminar
IMF Myeloma Bracelet - Imagine Moving Forward
Myeloma Minute - May 6, 2005
Bank On A Cure? Frequently Asked Medical Questions
Bank On A Cure? Scientific Advisory Board
Bank On A Cure? IMF Patient Programs and Services
Bank On A Cure? Brian Van Ness, Ph.D.
Brian G.M. Durie, M.D.
Susie Novis, President, International Myeloma Foundation
Bank On A Cure? Susie Novis, President, International Myeloma Foundation
IMF Hotline Coordinators Answer Your Questions
Supportive Care: Blood Tests
Dallas Patient & Family Seminar
Community Goals Lead to Results
IMF Receives Highest Four-Star Rating
Sorority Raises Funds for a Cure
Myeloma Foundation of Australia Inc.
Webcast of the Official Launch of BANK?ON?A?CURE?
So, What?s Up With Revlimid?
Myeloma Minute - May 16, 2005
2005 Brian D. Novis Research Grants
Did You Know: What Causes Hyperviscosity in Multiple Myeloma?
JC?s Support for Myeloma Patients Grows
Myeloma Minute - May 22, 2005
Myeloma Minute - July 10, 2005
I Have Myeloma....What's Next?
Team Milers Against Myeloma
San Diego Rock ?n Roll Marathon
First meeting of the Israeli Myeloma Working Group to be held on July 29, 2005
INTERNATIONAL NON-PROFIT DECORATES PACIFIC NORTHWESTERN MEDICAL COMMUNITY WITH ANNUAL RIBBON OF HOPE
Myeloma Minute - August 14, 2006
Myeloma Minute - July 3, 2005
Documentary Film Company Searching for Myeloma Patients Who Are Taking Thalidomide
Understanding Quadramet®
Myeloma Minute - July 31, 2005
Myeloma Minute - July 22, 2005
History is Made with the First Meeting of the Israeli Myeloma Study Group
Ministry Recap and Reflection - July 2005
Myeloma Minute - August 22, 2005
Multiple Colors for Multiple Myeloma
Myeloma Minute - September 2, 2005
Myeloma Minute - September 13, 2005
An old hometown needs help
ACTION ALERT! Congress Can?t Agree on Spending Bill.
IMF - ????? ??????, ????? ?? ????? ?
FDA postpones approval of Revlimid? for MDS
But Celgene says filing for myeloma remains on track
Patient Perspective: A Conversation with Tim and Donna Egan
Patient Perspective: Cancer Etiquette
Apprendimento VELCADE^® (bortezomib) per iniezione
Myeloma Minute - November 21, 2005
Third Annual Myeloma Days in Istanbul Draws Over 100 Attendees
Phase II VELCADE® Clinical Trials
Myeloma Minute - January 10, 2006
Myeloma Minute - October 28, 2005
Phase IV REVLIMID? Trial (Expanded Access Protocol or EAP)
REVLIMID? EXTENDS SURVIVAL WITH POSITIVE IMPLICATIONS FOR A WIDE RANGE OF BLOOD CANCERS
IMF Chair, Dr. Brian Durie, featured in Scientific American article DNA on the Loose: Next-Gen Blood Tests Tap Free-Floating Genetic Material
IMF Says Revlimid Approval Could Benefit Patients Throughout Europe
IMF: La recomendaci?n de la aprobaci?n de REVLIMID® puede beneficiar a pacientes en toda Europa
Der Vorschlag zur Genehmigung von REVLIMID(R) k?nnte sich laut der International Myeloma Foundation zum Patientenwohl in ganz Europa auswirken
Международный фонд борьбы с миеломой заявляет о том, что рекомендация одобрить REVLIMID(R) может помочь больным во всей Европе
La International Myeloma Foundation indique que la recommandation d'autorisation de mise sur le march? du REVLIMID(R) pourrait profiter aux patients de toute l'Europe
CAUTION ABOUT USE OF ERYTHROPOIETIN PRODUCTS
Kenneth C. Anderson Honored by IMF with 2005 Robert A. Kyle Lifetime Achievement Award
Over 200 Attend 2nd Annual Patient & Family Seminar in Madrid
Millennium invites Support Group Leader to XIth Myeloma Workshop in Kos, Greece
Over 300 In Attendance at Third Italian Patient & Family Seminar
ECOG REVLIMID? TRIAL HAS RESUMED
Myeloma Minute - November 7, 2005
Living Well with Multiple Myeloma Teleconference - Pain Management
Heinz Ludwig ASH 2005
Webcast of Dr. Hartmut Goldschmidt at ASH 2005
Webcast of Dr. Meryl Beksac at ASH 2005
Revlimid Update: Where Do We Stand?
Total Therapy III Update
Medicare Deadline Reminder
Un informe del Segundo Congreso Europeo para Enfermedades Hematol?gicas
Report from the 2nd European Congress on Hematological Malignancies
Living Successfully with Multiple Myeloma
Czech Patient & Family Seminar - September 2-3, 2005
Music Against Myeloma
Report from Madrid
I met Dr. Brian Durie more than 30 years ago...
Myeloma Minute - Special Edition:
FDA Grants 'Priority Review' for Revlimid
Don?t be misled by news reports that say thalidomide stops working for myeloma patients.
Myeloma Minute - March 14, 2006
Myeloma Minute - March 21, 2006
Fourth Annual Robert A. Kyle Lifetime Achievement Award Tribute Journal
Fourth Annual Robert A. Kyle Lifetime Achievement Award Event Details
Fourth Annual Robert A. Kyle Lifetime Achievement Award Sponsors
Verwirrende neue Geschichten ?ber die Effektivit?t von Thalidomid; was bedeutet dies?
Study Finds Patients Agree on Ideal Physician Behaviors
Eine Studie der Mayo-Klinik findet Patienten-Zustimmungzum idealen Verhalten von ?rzten
Mozobil ? ein neues Medikament zur Sammlung von Stammzellen
Kongressbericht: Symposium ?Das Multiple Myelom 2006: auf dem Weg zur Heilung??
Revlimid? Accepted by EMEA for Evaluation as Oral Therapy for Relapsed or Refractory MM
Myeloma Minute - April 5, 2006
Myeloma Minute
September 28, 2011
Marktzulassungsantrag für LENOLIDAMID von EMEA zur Überprüfung angenommen
EMEA sta valutando LENOLINOMIDE come terapia orale per la cura di pazienti con mieloma recidivo
L'EMEA accepte d'?valuer la demande d'autorisation de mise sure le march? de la LENALIDOMIDE
La EMEA analiza la solicitud de comercialización de LENALIDOMIDA
Revlimid? Accepted by EMEA for Evaluation as Oral Therapy for Relapsed or Refractory MM
Myeloma Minute - April 11, 2006
Myelom Merkur - Ausgabe, April 2006
Our Guiding Light Shines Bright
16th Anniversary Gala Sponsors
Scheduled Speakers for the Fourth Annual Robert A, Kyle Lifetime Achievement Award
The IMF Launches Website for Global Spanish-Speaking Community
La IMF lanza un sitio Web para la comunidad mundial de habla espa?ola
Myeloma Minute - April 19, 2006
συνέντευξη - Dr. Meletios-Athanassios Dimopoulos
Polskie Stowarzyszenie Pomocy Chorym na Szpiczaka
The Yin and Yang of Long-Term Survivorship
American Society of Hematology - 47th Annual Meeting
Dear Reader
The Stafford Family Funds Myeloma Research Grant
Flavia Hiatt Shares Her Story
2006 IMF Brian D. Novis Research Grant Awards
Combination Therapy with VELCADE plus Melphalan & Prednisone
Pain Management in Multiple Myeloma
Transplant Nutrition
My Life With Myeloma
Challenging Cancer with the Power of Painting
Board of Directors Profile: Matthew Robinson
IMFers MAKE A DIFFERENCE!
2005 Member Fundraisers in Review
2005 Support Group Recap
Central Nebraska Myeloma Support Group
The IMF Returns to St. Petersburg, Russia
IMF Hotline Coordinators Answer Your Questions
Dalsu Baris, MD, PhD
House Budget Inaction Stalls Senate?s Cancer Funding Momentum
Myeloma Minute - April 26, 2006
Myeloma Minute - May 2, 2006
Myelom Merkur - November 2008
House Leadership Presses for Budget Bill Opposed by Health Advocates
Myeloma Minute - May 10, 2006
House Leadership Uses Obscure Procedural Move to Cap Spending Levels
Myeloma Minute - May 18, 2006
Dear Reader
Patient Perspectives: NUMBERS DON'T LIE, or do they?
IMF Around the Globe: Israeli Association of Myeloma Patients
Sixth Annual Support Group Leader Retreat
Making Clinical Trials More Patient-Friendly
Pathogenesis and Maintenance of Multiple Myeloma
MOZOBIL?, a potential new agent for Stem Cell Harvesting
Patient Experience: One Day at a Time...for 18 Years
Education, Advocacy, and Awareness: Profile of Robin Tuohy
IMF Hotline Coordinators Answer Your Questions
The Multiple Myeloma ListServe
IMF Around the Globe: ?The Greater Montreal Multiple Myeloma Support Group
Member Events: Gary C. Heuer, Jr. Memorial Golf Tournament
Fundraising: Rocking in Rhode Island
Fundraising: Katie's Birthday Charity Bash
South Florida's Dynamic Duo: Cindy Feltzin and Vicki Anderson Ferraro
IMF Board Member Interview with Benson and Carol Klein
Insights into New Myeloma Tx: Revlimid Study Tops List of Investigations that may Benefit Patients
Member Events: 4th Annual MMAMM Benefit Keeps Lee Grayson's Memory Alive
On the Road with the IMF Support Team
Advocacy Update: Senators Outraged by Decreased Research Funding
THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS FDA APPROVAL OF THALOMID? FOR MYELOMA PATIENTS
Myeloma Minute - May 24, 2006
Ralph Ferrizzi Memorial Golf Tournament
My Journey Through Myeloma
Myeloma Minute - May 31, 2006
ASCO 2006 Overview with Dr. Durie
Myeloma Minute - June 7, 2006
2006 IMF Support Group Leaders? Retreat
Report from ASCO 2006
ASCO 2006 INDUSTRY NEWS
Myeloma Minute - June 14, 2006
7th Annual JC Golf Tournament a Stellar Success!
IMF Receives Grant from Goldman Philanthropic Foundation for Bank On A Cure®
16th Anniversary Gala Sponsor Opportunities
2006 Robert A. Kyle Lifetime Achievement Award; Report from the Dinner Chairs
The International Myeloma Foundation Unveils Plans for MYELOMA MOBILE to Travel Across the U.S. this Summer
1845
AMEN's First Anniversary
AMEN's First Anniversary
Myeloma Minute - June 21, 2006
REVLIMID? APPROVAL FOR MYELOMA CAN BE LIFE-CHANGING FOR CANCER PATIENTS
Myeloma Minute Special Edition: Revlimid® Approved for Myeloma!
Prediction of response to therapy with clarithromycin/lenalidomide/dexamethasone (BIRD) in MM
Lenalidomide plus high-dose dex provides improved overall survival compared to high-dose dex alone
Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma.
Myeloma Minute - June 30, 2006
Correlation of bone marrow angiogenesis & response to thalidomide Dexamethasone in multiple myeloma
An Overview of Key Presentations at ASCO 2006
Un resumen de las presentaciones claves de ASCO 2006
Myeloma Minute - July 7, 2006
ASCO 2006
Partnership for Cure's Concert for Cures Nets $25,000 for Bank? On A Cure
An Overview of the Role of Novel Therapies in Previously Untreated Myeloma
Comparison of lenalidomide with dexamethasone to dex alone in patients who've received prior thalid
Multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dex vs dex
Dose-escalating & pharmacologic study of bortezomib in adult cancer pts with impaired renal function
Single-agent bortezomib in previously untreated MM:
Results of a phase II multicenter study.
Randomized, Active-controlled Study of Denosumab (AMG 162) in Breast Cancer Patients with
Rock On!
ASCO 2006: A Commentary
?Qu? es el Mieloma?
Update on Multicenter Atiprimod Trial
Myeloma Minute - July 26, 2006
Part I
AMEN Seminar for Hematology Residents
AMEN Hosts Myeloma Seminar for Hematology Residents
Myeloma Minute - July 26, 2006
Part II
RUN THE NYC MARATHON AND FIGHT MYELOMA
ASCO 2006
PX-171-011 – A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma (FOCUS)
ASCO 2006
Dr. Bladé - A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Summer 2006 Myeloma Today in PDF
Spring 2006 Myeloma Today in PDF
Myeloma Minute - August 6, 2006
Leading Cancer Experts Conduct Philadelphia Seminar on MM Treatment as New 'Model' for Cancer Care
Comprendre Revlimid®
Comprendre La Dexaméthasone et Autres Stéroïdes
Out and About in Beverly Hills
Myelom Merkur - Ausgabe, August 2006
Myelom Merkur - Ausgabe, Mai 2006
An IMF tip-sheet: How to Round Out Your Trip to the IMF's 16th Anniversary Gala
Myeloma Minute - August 30, 2006
Myeloma Minute - May 1, 2007
Report from the 2nd Annual Czech Myeloma Group Patient Seminar
INTERIM FINDINGS FROM GLOBAL TRIAL EXTEND POSITIVE BENEFITS OF VELCADE TO NEWLY DIAGNOSED PATIENTS
Live Auction Items for the IMF's 16th Anniversary Gala on October 21
Igor Sill
The International Myeloma Foundation Says the Kennedy-Hutchison Cancer Bill Will Reinvigorate War on Cancer
E. Michael D. Scott
An American in Paris?
Myeloma Minute _ September 22, 2006
Have You Made Your New Year's Resolutions Yet!
ASH 2006 Highlights for Patients with Myeloma
Report from the 4th Annual Paris Patient & Family Seminar
Myeloma Minute - October 5, 2006
Advocacy Update - September 15, 2009
Advocacy Update - September 1, 2009
Report from the Fourth Annual Italian Patient & Family Seminar
Myeloma Minute - October 17, 2006
IMF -????? ?????, ????? ?? ????? ? - VELCADE®
????? ????? ?????? - (Thalidomide) ???????? ?????????.
Fall 2006 Myeloma Today in PDF
Conociendo Revlimid
What a Night! Report from the IMF's 16th Anniversary Gala
Myeloma Minute - November 3, 2006
New IMF Nurse Leadership Board Meets to Develop Recommendations for Care
The IMF in Atlanta
Myeloma Minute - November 11, 2006
Conociendo Dexametasona y Otros Esteroides
Das Handbuch zur Ballon Kyphoplastik „Ballon Kyphoplastik und Myelom-induzierte Wirbelfrakturen verstehen"
国際骨髄腫財団：国際癌会議における数々の研究報告。新治療方法に関して血液癌患者に明るい展望
 The Use of Velcade as First-Line Therapy in High-Risk Myeloma
The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
The Genetic Contribution to the Etiology of Thalidomide-Associated VTE
Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
A Phase I Study of Novel Proteasome Inhibitor PR-171 (carfilzomib)
Identification of Mutations in the NFkB Pathway That Predict Velcade Response
Velcade Added to High-Dose Cytoxan and GCSF as a Mobilization Regimen for Stem Cell Collection Prior to HDT

Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
A Randomized Study of Lenalidomide with High- or Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Myeloma
Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
SNP Association with Event-Free Survival (EFS) in Myeloma from Two Phase III Trials Using the Bank On A Cure SNP Chip

Relationship Between Quality of Response to Velcade and Clinical Benefit

A Phase I Study of HCD122 (formerly CHIR-12.12), a Monoclonal Antibody to CD40, in Relapsed/Refractory Myeloma

A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma

Analysis of Phase III Study of Revlimid/Dexamethasone vs. Dexamethasone Alone in Patients >65 Years

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma

An Analysis of Response Criteria Post-Stem Cell Transplant in AL Amyloidosis

An Overview of ASH 2006
Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma

Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma

New Proteasome Inhibitor NPI-0052

A Retrospective Analysis of Three Induction Regimens for Newly Diagnosed Myeloma Prior to Transplant

A Retrospective Analysis of the Significance of Measurable Disease at Time of Transplant

A Retrospective Analysis of High-Dose Therapy in Patients with Renal Insufficiency

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma

An Overview of ASH 2006
Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma in Patients with Elevated Baseline Serum Creatinine

Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma

An International Randomized Trial of Thalidomide/Dexamethsone vs Dexamethasone Alone

A Retrospective Study of the Significance of VGPR/CR in the IFM 99 Trials

An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma

Prospective Randomized Comparison of Double Transplant with Melphalan 200 vs Triple Transplant with Melphalan 100

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma

IMF Promotes David Smith to Executive Director
2007 Brian D. Novis Grant Winners Announced at ASH
Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma

Phase I Study of KOS-953 + Velcade in Patients with Relapsed/Refractory MM
A Retrospective Study of the Significance of Complete Response (CR) on Outcomes in Myeloma Treatment

A Subset of Revlimid/Dexamethasone vs Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
The Use of Velcade + Melphalan and Prednisone in Elderly Non-Transplant Patients

A Phase II Study of Alternating Velcade and Dexamethasone as Induction Therapy Prior to Transplant in Newly Diagnosed Patients

An Overview of Planned Randomized Clinical Trials for Newly Diagnosed Younger and Older Patients in Spain

Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma

Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma

Sue Sumpter's Blog from ASH 2006
Paula Van Riper's Blog from ASH 2006
Jack Aiello's Blog from ASH 2006
An Overview of ASH 2006
The IMF Mourns the Passing of Cathy Lebkuecher, winner of the Francesca Thompson Outstanding Service Award for her work with myeloma patients.
A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
A Dra. Hungr?a explica o que ? mieloma m?ltiplo e quais s?o os seus tratamentos.
A Dra. Hungr?a fala sobre a Epidemiologia de Mieloma Múltiplo na América do Sul
The Effect of Genetically Modified Measles Virus on Myeloma Cells in Vitro

A Phase I/II Study of Consolidation Therapy with Velcade after Tandem Transplant

Winter 2006 Myeloma Today in PDF
German Translation of The Effect of Genetically Modified Measles....
German Translation for Consolidation Therapy video
STUDY SHOWS VELCADE® PLUS DOXIL® IMPROVES SURVIVAL IN PREVIOUSLY TREATED PATIENTS WITH MYELOMA
Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2006
The F.O.R. (Friends of Richie) Benefit Story
IMF's Multiple Myeloma Quilt of Courage 5
Overview of ASH 2006 in Hebrew

Multiple Myeloma Quilt of Courage #5 - To Honor Tom Finnerty
Myeloma Quilt of Courage #5 - In Memory of Rich Ramsaier
Multiple Myeloma Quilt of Courage #5 - To Military and Ex-Military
Multiple Myeloma Quilt of Courage #5 - To Honor Jerry Simpson
Multiple Myeloma Quilt of Courage #5 - By Reino Melse Meenks
Multiple Myeloma Quilt of Courage #5 - In Memory of Fritz Steppat
Multiple Myeloma Quilt of Courage #5 - In Memory of Jim Potter
Myeloma Quilt of Courage # 5 - By Karen Maru
Myeloma Quilt of Courage #5 - In Memory of Christal Mann Albert
Myeloma Quilt of Courage #5 - In Memory of Dick T. Jordan, Jr.
Myeloma Quilt of Courage #5 - In Memory of Tim Woomer
Myeloma Quilt of Courage #5 - In Memory of Nancy Ann Phillips
Myeloma Quilt of Courage #5 - For Walter (Peter) Carr
Myeloma Quilt of Courage #5 - For Stanley Sablock
Myeloma Quilt of Courage #5 - By Debbie Tidwell
Myeloma Quilt of Courage #5 - To Honor All Those on the ACOR Myeloma Listserv
Myeloma Quilt of Courage #5 - By Myde Stocker
Myeloma Quilt of Courage #5 - In Memory of Bill Bertsche
Myeloma Quilt of Courage #5 - In Memory of Claire E. Wehrlen
Turn Your Vacations Into Donations!
Support Group Leader Blogs from ASH 2006
Myeloma Minute - January 23, 2007
LEADING CANCER EXPERTS TO CONDUCT LOS ANGELES SEMINAR ON MYELOMA TREATMENT AS THE "NEW MODEL" FOR CANCER CARE
Myeloma Minute - February 3, 2007
INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS
Myeloma Minute - February 13, 2007
2005 Brian D. Novis Grant Winners
ASH 2006 Multiple Myeloma Highlights for Physicians
IMF Travel Advantage Newsletter
Your Travel Helps Fund the IMF
David H. Vesole, MD, PhD, FACP
Treatment of Newly Diagnosed Myeloma Based on Mayo Clinic's mSMART
Heather Cooper Ortner Named IMF Vice President of Development
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Myeloma Minute - April 5, 2007
THE INTERNATIONAL MYELOMA FOUNDATION SAYS ECOG RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
International Myeloma Working Group
International Myeloma Workshop 2011
MONOCLONAL IMMUNOGLOBULIN AND THE NERVE, WALDENSTROM'S MACROGLOBULINEMIA
Dr. Leblond - Update in the Treatment of WM
International Myeloma Workshop 2011
MONOCLONAL IMMUNOGLOBULIN AND THE NERVE, WALDENSTROM'S MACROGLOBULINEMIA
Panel Discussion
International Myeloma Workshop 2011
CONSENSUS REPORT: Panel 1
Dr. Anaissie - Consensus guidelines for infection prophylaxis including vaccination?in?myeloma
CELGENE LAUNCHES NEW ?PATIENT SUPPORT COORDINATOR? PROGRAM AT IMF MEETING OF SUPPORT GROUP LEADERS IN PHOENIX
Route for Myeloma Mobile Finalized
New England Journal of Medicine Sites Myeloma as Concern for Firefighters at 9-11 Scene
IMF Satellite Symposium at ONS - a huge success!
Myelom Merkur - 3. Ausgabe, April 2007
Myelom Merkur - 5. Ausgabe, January 2007
Myelom Merkur - Januar 2007
2. Jahrgang, 1. Ausgabe
Myeloma Today Spring 2007 in PDF format
2nd Annual Music Against Myeloma Raises 10K for IMF
IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Myeloma Minute Special Edition: NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Myeloma Minute - May 22, 2007
URGENT Advocacy Alert for Myeloma Patients:Reimbursement at Risk for ESAs for Management of Anemia
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma.

Prediction of response and progression in multiple myeloma (MM) with serum-free light chains (sFLC): Corroboration of the International Myeloma Working Group (IMWG) criteria.

Current status of stem cell transplantation: When? How Many? Allogeneic v Autologous or Both?

A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma

Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.

Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma

Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.

Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma.

Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses.

COMUNICADO: La IMF dice que la aprobaci?n de REVLIMID(R) es un importante avance para los pacientes en Europa
La Fondation internationale du my?lome indique que l'autorisation de mise sur le march? de REVLIMID® par l'EMEA repr?sente un progr?s important pour les patients en Europe
Die internationale Myelom-Stiftung ist der Auffasung, dass die Marktzulassung von REVLIMID? durch die EMEA f?r die Patienten in Europa ein gro?er Fortschritt ist
2007 Robert A. Kyle Lifetime Achievement Award
KOS 2007: Solitary Bone and Extramedullary Plasmacytoma
KOS 2007: The role of Autologous Transplantation in Waldenstrom's Macroglobulinemia
KOS 2007: Establishment of an Amyloid-Forming Human Cell Line
KOS 2007: Serum Concentrations of Angiogenic Cytokines in Waldenstrom's Macroglobulinemia: The Ratio of Angiopoietin-1 to Angiopoietin-2 Correlate with Disease Severity
KOS 2007: Molecular Principles Underlying Myeloma
KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
KOS 2007: Molecular Lesions in Multiple Myeloma
KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
KOS 2007: The Scid-hu model for Multiple Myeloma
KOS 2007: Animal Models of Multiple Myeloma: An Overview
KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
KOS 2007: Pathophysiology of Myeloma Bone Disease
KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
DATA REPORTED AT A GLOBAL MEDICAL MEETING IN GREECE DEMONSTRATES IMPROVED SURVIVAL FOR A WIDE RANGE OF MYELOMA PATIENTS
KOS 2007: The Role of T-Cells in Multiple Myeloma
KOS 2007: Genetic Model of Multiple Myeloma
KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
KOS 2007: New Agents Targeting Myeloma Bone Disease
KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
THE NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION PRESENTS ?GUIDELINES FOR ENHANCED PATIENT CARE? AT INTERNATIONAL MEDICAL MEETING
KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
KOS 2007: Final Results of a Phase II PETHEMA Trial of Alternating Bortezomib and Dexamethasone as Induction Regimen Prior Autologous Stem Cell Transplantation (ASCT) in YOunger Patients with Multiple Myeloma (MM): Efficacy and Clinical Implications of Tumor Response Kinetics
KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
KOS 2007: Management of Toxicities from Novel Agents
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective?
Introduction
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Yes!
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? No!
KOS 2007: Targeting Beta 1 Integrin Mediated Survival Signals in Multiple Myeloma
KOS 2007: Response by SFLC and Marrow Flow Cytometry in MRC Myeloma IX
KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma
KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area
KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients
KOS 2007: Drug Resistance in Myeloma
Understanding ZIO-101
(Darinaparsin)
ASH 2009: Dr. Brian Durie, Cedars Sinai Comprehensive Cancer Center, Los Angeles, California
WALL OF MIRACLES CHAIRMAN'S CIRCLE
What is Myeloma?
Understanding Stem Cell Transplant
testing pommo system for minute...
KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents
KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Introduction

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Q & A

KOS 2007: The Importance of New and Evolving Response Criteria
KOS 2007: AKT as a Therapeutic Target in Multiple Myeloma
KOS 2007: DNA Vaccines to Suppress Myeloma
KOS 2007: Novel Immunotherapy Strategies in Multiple Myeloma
KOS 2007: Single VS Double Autologous Transplant
KOS 2007: Autologous Stem Cell Transplantation for MM: Analysis of Prognostic Factors
KOS 2007: The Role of Donor-Lymphocyte Infusion and Other Post-Transplant Strategies After Allografting in Multiple Myeloma
KOS 2007: Donor lymphocyte infusion and other posttransplant Strategies After Allografting in Multiple Myeloma
KOS 2007: European Myeloma Network: The Present and the Future
KOS 2007: Future Perspectives in the Management of Myeloma
KOS 2007: High-Resolution Mapping of Common Gains and Losses in Myeloma
KOS 2007: Microchips for Optimized Fish Screening in Myeloma
KOS 2007: Gene Expression Profiles as Prognostic Factors for High-Dose Therapy and Bortezomib in Patients with Multiple Myeloma
KOS 2007: Cathepsin G is Upregulated in Patients Treated with IMIDS
KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial
Kos 2007: Allogeneic Transplantation in Multiple Myeloma
KOS 2007: Is there still a place for high-dose therapy in the elderly myeloma patients?
KOS 2007: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
KOS 2007: AL Amyloidosis: Diagnosis and Prognosis
KOS 2007: AL Amyloidosis: Response, Assessment, and Treatment
KOS 2007: The Role of High-Dose Therapy in AL-Amyloidosis
KOS 2007: Light Chain Deposition Disease
KOS 2007: What?s New About the POEMS Syndrome?
KOS 2007: Paraproteinemia Related Neuropathies
Myeloma Today Summer 2007 in PDF format
MY MMAMM EXPERIENCE
Conociendo la t?cnica de detecci?n de Cadenas Ligeras Libres en suero
Watch a Short Video About the IMF
REPORT FROM AMEN'S SECOND ANNIVERSARY
Comprendere il Desametasone e gli Altri Steroidi
The International Myeloma Foundation Issues Prevention and Treatment Guidelines for Firefighters for High-Risk Cancer
Myeloma MInute - August 18,2007
Myeloma Minute - July 30, 2007
Myeloma Minute Special Edition - Concert for a Cause!
Understanding Anemia and Fatigue
We Mourn the Passing of IMF Board Member, Rich Saletan
Myelom Merkur - August 2007
ASCO 2007 Highlights for Patients
ASCO 2007 Highlights for Physicians
Comprendre les Tests des Cha?nes L?g?res Libres S?riques
IMF Satellite Symposium: Key Myeloma Questions for 2010
Diagnosis, Prognosis, and Risk Assessment in Multiple Myeloma
Help Us Learn More About Myeloma Patients
Myeloma Minute Special Edition - Celebrating Peter Boyle
Myeloma Minute Subscription
JOURNAL EDITORIAL DOCUMENTS DRAMATIC INCREASE IN SURVIVAL SINCE THE 1980?S
Myeloma Minute - November 29, 2007
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Freie Leichtketten-Tests verstehen
L?čba thalidomidem
L?čba Velcade
L?čba Revlimidem
Myeloma Minute - November 21, 2007
THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW FINDINGS REPORTED AT GLOBAL CANCER CONFERENCE REQUIRE NEW WAYS TO EVALUATE TREATMENTS
Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Dr. Robert Kyle - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Durie - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Jes?s San Miguel - Novel Agents at the 49th Annual American Society of Hematology Meeting (ASH) 2007
Elijah Alexander: ASH 2007: A Patient's Perspective
Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy
Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
Dr. Boccadoro - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Dr. Beksac - ASH 2007 G?ncel ?zet
Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma

Dr. Gertz - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
Dr. Blad? - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of W?rzburg
Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
Dr. Blad? - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress
Dr. Einsele - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in W?rzburg
Dr. Liebisch - Ein ?berblick ?ber den Klinische Studien in Ulm
Dr. Rowe - Information From The 2007 Annual Meeting of the American Society of Hematology (ASH)
Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress
4-? ??????????? ??????????? ???? ? ??????
Dr. Boccadoro - Una visione d?insieme dell?ASH 2007
Dr. Hajek - ASH 2007 - celkov? přehled
Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma

Dr. Blade - Un resumen de las presentaciones de ASH 2007
??? ????? ????????
Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients

Dr. Harousseau - Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2007
2008 Brian D. Novis Grant Award Recipients Announced at ASH 2007
THE INTERNATIONAL MYELOMA FOUNDATION SAYS STUDY SHOWS 90% OVERALL RESPONSE FOR PATIENTS WITH NEW REVLIMID? COMBINATION
Dr. Avet-Loiseau - Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2007
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Dr. Tosi - Una visione d?insieme dell?ASH 2007
Dr. De la Rubia - Un resumen de las presentaciones de ASH 2007
Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
Myeloma Today Winter 2007 in PDF
Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
Dr. Sezer - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Berlin
Dr. Goldschmidt - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien der GMMG und in Heidelberg
Dr. Mergenthaler - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Stuttgart
Dr. Salwender - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Hamburg Altona
Planning for Treatment With or Without Transplant
Balancing Efficacy, Toxicity, and Quality of Life for the Patient with Multiple Myeloma
Rolf Pelzing - European Myeloma Platform (EMP)
Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling
Rolf Pelzing - European Myeloma Platform (EMP)
La Fondazione Internazionale del Mieloma vede come imminente l?approvazione di un nuovo regime terapeutico per pazienti pi? anziani
La Fondation Internationale du My?lome d?clare que le nouveau r?gime de traitement pour les patients plus ?g?s pourrait bient?t ?tre approuv? en Europe
The Founding of AMEN
A Patient's Story
IMF Patient Handbook
THE IMF SAYS NEWLY DIAGNOSED PATIENTS COULD BENEFIT FROM FDA "PRIORITY REVIEW" OF VELCADE® FOR FRONT-LINE USE
A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop

Bank On A Cure® Updates from ASH 2006
Progress Report: Bank On A Cure® Research Initiative
Pilot VELCADE® Clinical Trials
Una Notte Memorabile
Molecular Pathogenesis of MGUS and Multiple Myeloma
Myeloma Manager™
Personal Care Assistant™ Version 4.0.2
International Myeloma Foundation Research Initiatives
IMF Public Service Announcement (PSA)
What Clinical Outcomes are You Looking to Achieve with Balloon Kyphoplasty on Your Cancer Patients?
Does the Bone Cement, Polymethylmethacrylate (PMMA), Do Anything to Tumor Cells
Do You Consider Balloon Kyphoplasty When Plasmacytoma is Present?
Does the Balloon Kyphoplasty Technique Increase the Introduction of Malignant Cells into the Spinal Canal or Bloodstream?
At What Stage of a Patient's Chemotherapy or Radiation Treatment Can They Receive a Balloon Kyphoplasty?
Physician Biographies
Can a Patient Receive a Balloon Kyphoplasty While Undergoing Chemotherapy?
What is Your Preferred Sequence with Balloon Kyphoplasty and Radiation Treatment?
Indications
How Quickly Have Patients Reported Pain Relief after Balloon Kyphoplasty?
Do You Have Any Concern that Inflating an Inflatable Balloon Tamp (IBT), Used During Balloon Kyphoplasty, May Push a Tumor Posteriorly?
Who is a Good Candidate for Balloon Kyphoplasty?
Adverse Effects
Disclosure Statement
Can Balloon Kyphoplasty be Performed in Severely Deformed Vertebral Bodies?
What's the Role of Balloon Kyphoplasty and Radiation for the Treatment of Cancer Related Vertebral Compression Fractures?
The Role of Vertebral Augmentation: Expert Opinions

Myeloma Today Spring 2008 in PDF
WHAT IS BANK ON A CURE®?
THE INTERNATIONAL MYELOMA FOUNDATION SAYS THALIDOMIDE APPROVAL IN EUROPE COULD PROVIDE SURVIVAL BENEFITS TO NEWLY DIAGNOSED MYELOMA PATIENTS
NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION FINALIZES GUIDELINES TO HELP NURSES MANAGE AND PATIENTS COPE WITH THE SIDE EFFECTS OF THERAPY
Consensus on Care: New Insights on Novel Therapies in Multiple Myeloma
Myelom Merkur - Juli 2008
A TEA IN D.C.
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW STUDIES SHOW LONGER SURVIVAL FOR MYELOMA PATIENTS AND IMPROVED RESPONSE TO TREATMENTS
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
Conversations at ASCO 2008:
Antonio Palumbo, MD
University of Torino and Italian Multiple Myeloma Study Group
Conversations at ASCO 2008:
S. Vincent Rajkumar, MD
Associate Professor of Medicine, Mayo Clinic
Myeloma Matrix VELCADE® Supplement
THE INTERNATIONAL MYELOMA FOUNDATION SAYS PREVIOUSLY UNTREATED PATIENTS COULD BENEFIT FROM FDA APROVAL OF VELCADE® FOR 'FRONT-LINE' USE
Report from the Third Anniversary of AMEN
Myeloma Minute - July 8, 2008
Myeloma Minute
May 18, 2008
Myeloma Minute
June 12, 2008
Myeloma Minute
May 8, 2008
Myeloma Minute
April 7, 2008
Myeloma Minute
March 28, 2008
Myeloma Minute
February 10, 2008
Myeloma Minute Special ASH Overview Issue
Press Alert & Happy Holidays from the IMF!!!
Conversations at EHA 2008
Heinz Ludwig, MD
Wilhelminen Hospital, Vienna, Austria

Conversations at EHA 2008
Roman H?jek, MD
Masaryk University, Brno, Czech Republic

Myeloma Today Summer 2008 in PDF
Myelom Merkur - Mai 2008
Myelom Merkur - M?rz 2008
Myelom Merkur - Dezember 2007
Myelom Merkur - Oktober 2007
How to Host an Afternoon Tea
Ask the Expert
Managing Side Effects of Novel Agents
Rx of Acute Compression Fractures with Balloon Kyphoplasty
How to Be a Better Patient
Myeloma 101
Standard Frontline Therapy
Understanding Serum Free Light Chain Assays
Stem Cell Transplantation in Multiple Myeloma
Bone Disease in Myeloma
How To Deal With Relapse?
Future Perspectives in Myeloma Management
Myeloma Minute
August 25, 2008
AN EDITORIAL BY DR. BRIAN DURIE FEATURED IN THE NEW ENGLAND JOURNAL OF MEDICINE
THE INTERNATIONAL MYELOMA FOUNDATION RECEIVES HEALTH IMPACT AWARD FOR EXCEPTIONAL SERVICE TO MYELOMA PATIENTS AND COMMUNITY
THE INTERNATIONAL MYELOMA FOUNDATION SAYS LIFE-CHANGING BENEFITS OF REVLIMID® RECOGNIZED BY THE PRESTIGIOUS PRIX GALIEN USA AWARD 2008
Dr. Brian G.M. Durie Research Publications Overview
THE INTERNATIONAL MYELOMA FOUNDATION SAYS PATIENT EXPERIENCE—LONGER SURVIVAL AND IMPROVED QUALITY OF LIFE—SUPPORTS ENCOURAGING DATA BEING PRESENTED AT THE ANNUAL HEMATOLOGY MEETING
Comprensione - Cifoplastica Percutanea con Palloncino e Fratture da Compressione Vertebrale indotte dal Mieloma
THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS EXPANSION OF VELCADE® FOR PREVIOUSLY UNTREATED PATIENTS IN EUROPE AND CANADA
Combined Federal Campaign (CFC)
Report from the Rome 2008 Patient and Family Seminar
The International Myeloma Foundation Praises UK REVLIMID? Proposal as Positive, Innovative Model for Reimbursement
The International Myeloma Foundation, the MDS Foundation and a Coalition of Patient Advocacy Organizations Call for Updated Rules for Reimbursement, Access and Approvals for New and Existing Cancer Treatments.
Dear Members of the IMF Community
THE INTERNATIONAL MYELOMA FOUNDATION ANNOUNCES NEW THREE-WAY RESEARCH AGREEMENT WITH NOBEL PRIZE WINNER LUC MONTAGNIER AND HOWARD URNOVITZ OF CHRONIX BIOMEDICAL
THE INTERNATIONAL MYELOMA FOUNDATION CALLS FOR ALL PATIENTS TO HAVE ACCESS TO THE NOVEL THERAPIES FOR MYELOMA
2nd Annual IMF Comedy Celebration Benefiting the Peter Boyle Memorial Fund Raises Over $600,000 for Myeloma Research
Dr. Rajkumar - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA

ASH 2008 - CASE STUDY 1: A MULTIPLE MYELOMA PATIENT INELIGIBLE FOR TRANSPLANTATION
"Evidence-Based Approaches for Transplant-Ineligible Patients"

ASH 2008 - CASE STUDY 2: A TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENT
"Role of Transplantation and Maintenance Therapy"

ASH 2008 - CASE STUDY 3: MULTIPLE MYELOMA PATIENT FOR WHOM TRANSPLANTATION ELIGIBILITY IS UNCERTAIN
"Evidence-Based Approaches for Induction Therapy"

Myeloma Today Fall 2008 in PDF
ASH 2008 - CASE STUDY 4: A MULTIPLE MYELOMA PATIENT WHO RELAPSES FOLLOWING INDUCTION THERAPY
"Novel Approaches for the Treatment of Relapsed/Refractory Myeloma"

Dr. Rajkumar - ASH 2008 - Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
THE INTERNATIONAL MYELOMA FOUNDATION SAYS MOZOBIL? APPROVAL COULD BENEFIT MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTS
Dr. Ludwig - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress 2008
Dr. Anderson - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA

Dr. Landau - ASH 2008 - Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response
Dr. San Miguel - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan?Prednisone Versus Melphalan?Prednisone in Newly Diagnosed Multiple Myeloma

Dr. San Miguel - ASH 2008 - Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Dr. Palumbo - ASH 2008 - A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients

Dr. Palumbo - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients

Dr. Palumbo - ASH 2008 - Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Dr. Morgan - ASH 2008 - Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Dr. Morgan - ASH 2008 - High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma

Dr. Morgan - ASH 2008 - CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

Dr. Morgan - ASH 2008 - Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients

Dr. Beksac - ASH 2008 - HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM)

Dr. Zonder - ASH 2008 - Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

Dr. Lacy - ASH 2008 - Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Dr. Kumar - Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Dr. Kumar - ASH 2008 - Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Dr. Kumar - ASH 2008 - Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Dr. Lokhorst - ASH 2008 - Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Dr. Lokhorst - ASH 2008 - Overview of ASH 2008 in Dutch
Myelom Merkur - April 2009
Dr. Hajek - ASH 2008 - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance

Dr. Salwender - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Hamburg Altona

Dr. Bensinger - ASH 2008 - A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Dr. Dispenzieri - ASH 2008 - Primary Therapy with Bortezomib?the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02

Dr. Jakubowiak - ASH 2008 - Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Dr. Jakubowiak - ASH 2008 - Initial Treatment with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Dr. Lonial - ASH 2008 - A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Dr. Lonial - ASH 2008 - A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration

Dr. Knop - ASH 2008 - Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial
Dr. Knop - ASH 2008 - Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial

Dr. Petrucci - ASH 2008 - Efficacy and Safety of Re-Treatment with Bortezomib (Velcade?) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial

Dr. Reece - ASH 2008 - Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid?) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Dr. Reece - ASH 2008 - Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion

Dr. Reece - ASH 2008 - The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

Dr. Englehardt - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Freiburg
Dr. Kaufman - ASH 2008 - First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Dr. Pozzi - ASH 2008 - Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease

Dr. Santo - ASH 2008 - AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β
Dr. Barlogie - ASH 2008 - Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Dr. Gertz - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008 in San Francisco, CA and
Dr. Miki - ASH 2008 - KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts

Dr. Goldschmidt - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien der GMMG und in Heidelberg
4-? ??????????? ??????????? ???? ? ??????
The International Myeloma Foundation Supports Legislation to Require Equal Insurance Reimbursement for Oral Cancer Drugs
IMWG Guidelines for Facilities and Services for the Management of Myeloma Patients
Dr. Goldschmidt - ASH 2008 - Inhibition of Aurora-Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma

Dr. Wijermans - ASH 2008 - Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

Dr. Van Ness - ASH 2008 - Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma

Dr. Vogl - ASH 2008 - Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Dr. Avigan - Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma
Dr. Gramatzki - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Keil
Dr. Blad? - ASH 2008 - Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade?)/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade? As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

4-? ??????????? ??????????? ???? ? ??????
Dr. Vij - ASH 2008 - Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Dr. Drach - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Wein

Dr. Niederwieser - ASH 2008 - Overview of the European Bone Marrow Transplant Group (EBMT)

Dr. Weber - ASH 2008 - Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

Dr. Munshi - ASH 2008 - Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients

2009 Brian D. Novis Grant Award Recipients Announced at ASH 2008
Dr. Knop - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Würzburg
Myeloma Merkur - Dezember 2008
International Myeloma Working Group at ASH 2009
Myeloma Advocacy Update - March 30, 2010
Dr. Sonneveld - ASH 2008 - Overview of ASH 2008 in Dutch
Dr. Bergsagel - ASH 2008 - The Genetic Origin of Myeloma
Dr. Cavo - ASH 2008 - Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma; Up-Front Response Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities
Dr. Wijermans - ASH 2008 - Overview of ASH 2008 in Dutch
Dr. Richardson - ASH 2008 -
Dr. Jagannath - ASH 2008 - Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma
Dr. Harousseau - ASH 2008 - Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan?Prednisone Versus Melphalan?Prednisone
Dr. Harousseau - ASH 2008 - Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2008
Dr. Harousseau - ASH 2008 - Velcade-Dexamethasone versus VAD as Induction Treatment Prior to ASCT in Newly Diagnosed MM. Updated Results of the IFM2005/01 Trial.
Green Tea Blocks Benefits Of Cancer Drug
Genetic Changes in Myeloma: Prognostic Implications
IMF Live Webcast From the XIIth International Myeloma Workshop
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: Nurse Perspective
Redefining Risk Using Cytogenetics Changes
Role of FISH in Myeloma Risk Stratification
Role of FISH in Myeloma Risk Stratification
High Throughput Profiling in Myeloma Pathobiology and Prognosis
New Insights In to the Molecular Basis of MM Pathogenesis & Prognosis
Inhibition of Signaling Cascades by Histone Deacetylase Inhibitors & AKT
Role of Hsp90 in Myeloma
Using Kinase Directed SiRNA Screen to Study Signaling Cascade in Development of Drug Resistance
Targeting NFkB Signaling in Myeloma
Waldenströms Award Lecture
Novel Antigenic Targets for Immunotherapy in Myeloma
BAFF Signaling in Myeloma
Antibody-based Therapies in Multiple Myeloma
Targeting the Right Patients to Achieve Overall Survival and Time to Progression Benefits
Disease Control with active Long-Term Treatment
Cure Versus Control: Shifting the Treatment Paradigm in Newly Diagnosed Multiple Myeloma
Induction Therapy and Timing of ASCT
New Options for Elderly Patients with Newly Diagnosed Multiple Myeloma
Case Presentation and Interactive Case Discussion
Statement from the IMF on Insurance Inequities
Immunomodulation: The Cornerstone of the Treatment of Multiple Myeloma
Deep Vein Thrombosis (DVT) Prophylaxis
Management of problems with stem cell mobilization
Prevention & Management of Drug-Induced Peripheral Neuropathy in Myeloma
p62 - a Potential Target for Blocking Microenvironmental Support of Myeloma
Migration and Homing in Multiple Myeloma
Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature
The Effect of Novel Antimyeloma Agents on Bone Metabolism
(IFM) Phase III Studies that have been Completed by the IFM Group in Multiple Myeloma
(IFM) Phase III Studies That are On-going and Future Planned studies by the IFM Group in Multiple Myeloma
(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the US Groups in Multiple Myeloma
(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the Canadian Group in Multiple Myeloma
(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Italian and Spanish Groups in Multiple Myeloma
(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Various Northern European Groups in Multiple Myeloma
Lenalidomide, bortezomib, and dexamethasone has notable activity in high-risk frontline myeloma
Bortezomib, dexamethasone, cyclophosphamide, lenalidomide (VDCR) has high efficacy in frontline myeloma
Prolonged therapy improves quality of response, and CR associated with superior outcomes, with VMP
A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients
MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study
First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycin, Dexamethasone (PAD) vs VAD as induction treatment prior to High Dose Melphalan (HDM) in patients with multiple myeloma (MM)
Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma
Panobinostat & Bortezomib Phase I Trial in Multiple Myeloma
Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
Phase 2 Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
Extended follow-up results of BiRD therapy: prolonged responses achieved
MRC Myeloma IX: Preliminary Results From The Intensive Pathway Study
Lethal and bortezomib-sensitizing targets in myeloma identified by genome-scale RNAi Screening
DNA DSBs induction by Zalypsis, a novel marine compound, results in potent antimyeloma activity
Proteomic analysis of Multiple Myeloma identifies upregulation of the novel protein CRIK
aCGH in Vk*MYC mice identifies genetic changes shared with human MM
MicroRNA expression profiling in multiple myeloma: correlation with genetic abnormalities
Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
Guidelines for the Uniform Reporting of Clinical Trials in Myeloma: Report of the IMW Consensus Panel
Guidelines for Stratification of Risk In Multiple Myeloma: Report of the IMW Consensus Panel
Guidelines for Standard Investigative Work-Up in Myeloma: Report of the IMW Consensus Panel
Statistical Issues in the Design and Analysis of Clinical Trials in Myeloma
New Mobilization and Conditioning Strategies
Timing of Transplant in the Era of New Drugs
Number - Single vs Double
Total Therapy
Allogeneic Transplant in Multiple Myeloma - Allografting for Myeloma: Mini? Maxi? Or Something in Between?
Post Transplant Maintenance
HOVON-50 Final Analysis of Thalidomide Combined with Adriamycine, Dexamethasone and HDM
Long-term Follow-up Results of IFM9903 and IFM9904 Rrials: RIC versus ASCT
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma ? a Prospective Trial
A Phase III Study of MEL200 versus MEL100 in Newly Diagnosed Myeloma Young Patients
Dex/Thal as Induction and Maintenance Treatment in Elderly Patients with MM : a Randomized Trial
A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
Post-ASCT Thalidomide Consolidation Further Prolongs PFS For Patients That Have Already Achieved A Complete or Very Good Partial Response
Len/Dex+/-Bortezomib for Advanced Myeloma According to Prior Neuropathy: the Impact of Cytogenetics
Management of Anemia in Multiple Myeloma Patients with Anemia: Findings from the A.C.T. Study
A Phase 3 Trial of Kyphoplasty Versus Nonsurgical Care for Cancer Patients with Vertebral Fractures
The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma ? An Update
Aurora-kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma
CAL-101 a Selective Inhibitor of PI3K p110δ for the Treatment of Multiple Myeloma
Targeting c-Myc Expressing Multiple Myeloma (MM) by Inhibiting Cyclin Dependent Kinase 1 (CDK1)
Efficacy and Safety of anti-b2M mAbs to Treat MM
IL21 Induces Myeloma Cell Growth via IGF1 Autocrine Loop
IL-17 Promotes Tumor Cell Growth & Survival, and Inhibits Immune Function in Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS): A Disease in Progression
Immunophenotyping of Plasma Cell Disorders
Can We Treat MGUS and Smouldering Myeloma?
Novel Agents in the Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Multiple Myeloma, and Skin Changes)
Understanding Pathogenesis to Improve Care in Amyloidosis
Improving Care for Patients with Amyloidosis
Pathogenesis, Biology and Diagnosis of Waldenstrom Macroglobulinaemia
Novel Treatment Options in Waldenstrom Macroglobulinaemia
Simultaneous use of Novel Agents in Induction Therapy
Sequential use of Novel agents in Induction Therapy
Therapy Should be Based on Risk Satisfaction - Favor
Therapy Should be Based on Risk Stratification - Against
Is there a role for Allo Tx? - Against
Is there a role for Allo Tx? - Favor
US/DFCI - New Agents
Early Combination Studies - "New Combination Approaches for MM"
New Proteasome Inhibitors
Anti Angiogenic Agents
Novel Bone Targeting Agents in Myeloma
New Imids
Lenalidomide Inhibits the Multiple Myeloma Cell-Survival Factor IRF4/MUM1
Centrosomal Clustering ? a Novel Therapeutic Target for Multiple Myeloma
Whole Body MRI in Asymptomatic Plasma Cell Disease
Is There a Place for Allogeneic Transplantation in Myeloma in the Era of Novel Agents?
Superiority of VTD Over TD Incorporated Into ASCT for Newly Diagnosed MM
Complete Response As A Marker Of Patient Outcomes
Improving Options For Frontline Management Of Multiple Myeloma
Evolving Treatment Options For Patients Not Eligible For Transplant
Optimizing Novel Therapies, Sequencing of Agents and Retreatment Options
Should Myeloma Therapy Be Based on Risk Stratification?
Future Directions in Multiple Myeloma Treatment. What can we Expect in the Next 10 Years?
Future Perspectives/Closing Ceremony
PRESENTATIONS FROM THE XIITH INTERNATIONAL MYELOMA WORKSHOP IN WASHINGTON, DC
FEBRUARY 26 - MARCH 1, 2009
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: Patient Perspective
The IMF is blogging from the XIIth International Myeloma Workshop in Washington, DC!
The International Myeloma Foundation ? Webcasting Live from the Scientific Sessions at the XIIth International Myeloma Workshop
Testing event calendar
Myeloma Today - April 2002
Dr. Brian Durie Receives the Prestigious Waldenström's Award in Recognition of His Many Contributions to the Field of Multiple Myeloma
The Black Swan Approach, or Cure = MC⁵
By Brian G.M. Durie, MD
March is IMF Myeloma Awareness Month!
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: What's of Importance to Patients for Their Future
Understanding Bisphosphonates Video with Japanese Subtitles
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: What's of Importance to Patients Today
International Myeloma Working Group Guidelines for Serum Free Light Chain Analysis in Multiple Myeloma and Related Disorders
Dr. Durie featured in BioWorld® Today article With Advances in Genomics, Exosomes Broaden Horizons
The International Myeloma Foundation Says Medicare Decision to Cover PET Scans Can Improve Disease Staging and Treatment Planning
Myeloma Today Spring 2009 in PDF
ASCO 2009: Jagannath: Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).
Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
Carfilzomib in Patients with Relapsed Multiple Myeloma (PX-171-004)
ASCO 2009 - Durie: Highlights
ASCO 2009 - Rajkumar: Highlights
ASCO 2009: Siegel: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2009: Vij, PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.
ASCO 2009: Shah: Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients.
ASCO 2009: Palumbo: A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients.
ASCO 2009: Baz: Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM).
ASCO 2009 - Brown: Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3).
ASCO 2009- Hofmeister: Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM).
ASCO 2009 - Anderson: Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.
ASCO 2009 - Anderson: Highlights
ASCO 2009 - Richardson: Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.
ASCO 2009 - Stadtmauer: Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients.
ASCO 2009 - Knop: Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial.
ASCO 2009 - Voorhees: A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2009 - Crowley: Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival.
ASCO 2009 - Kapoor: Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM).
ASCO 2009 - Niesvizky: PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results.
ASCO 2009 - Shaughnessy: Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3).
ASCO 2009 - Barlogie: Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials.
Do You Have an Opinion about Health Care?
ABC is soliciting questions or comments from viewers about health reform.

Messager de My?lome
La International Myeloma Foundation e l'Associazione Schirinzi A. Mario uniscono le loro forze per la lotta contro il mieloma multiplo
Spotlight on MUSIC AGAINST MYELOMA
IMF ADVOCACY CENTERED ON PATIENT PRIORITIES
Contact IMF Advocacy Staff
????????? ????????????? ??????? ?????? ?? ??????? ? ???????????? ?? ??????????? ???? ??????? ???????????? ? ??????????? ? ??????????? ????????????? ???????
???????????? ????????, ?????????? ? ??????????? ?????????? ? ????????????, ??? ???????
?????? ????????????? ???????? ???????????? ??????? ??? ????????????? ???????
4-? ??????????? ??????????? ???? ? ??????
Afternoon Tea in Washington DC
2009 Virtual Founders Summit
What YOU Can DO
Patient Care
Advocacy Update - August 3, 2009
3rd Annual Comedy Celebration
Benefiting the Peter Boyle Memorial Fund
ASH 2009: Bank On A Cure^®
Common Symptoms Of Multiple Myeloma

Statement on the passing of Senator Kennedy
Comprendre la greffe de cellules souches
To make a difference, you need to make your voice count!
About the Peter Boyle Memorial Fund
Comedy Celebration 2009 Event Sponsors
Comedy Celebration 2009 Event Committee
Comedy Celebration 2009 Tickets & Pricing
Comedy Celebration 2009 Sponsorship and Advertising Opportunities
Media Information for Comedy Celebratiaon 2009
Comedy Celebration 2009 Journal Specifications and Submission Requirements
Comedy Celebration 2009 Silent Auction
Comedy Celebration 2009 Opportunity Drawing
Tributes and Memorials
Founders' Circle Summit
Member Events
Organize Your Member Fundraiser
Matching Gifts / Corporate Responsibility
Combined Federal Campaign
Veterans Against Myeloma
Major Giving
Getting Involved
Contact The Development Department
ebay and Shop For The IMF
Planned Giving: The Brian D. Novis Legacy Society
The Small Print
Dr. Brian Durie
Ask-the-Experts
Open Forum Discussion with Dr. Brian G.M. Durie, Dr. Frederick Smith and Dr. Robert Kyle
How to Be a Good Patient
Michael Katz
Managing the Side effects of Novel Agents
Kena Miller,RN, MSN, FNP
Understanding Scientific Literature
Allan Weinstein, PhD
Myeloma 101/Overview
Dr. Robert Kyle
Current Options for Frontline Therapy
Dr. Brian Durie
Understanding Serum Free Light Chain Assays
Dr. Karen Van Hoeven
Role of Bone Marrow Transplant in the Treatment of Myeloma
Dr. Edward A. Stadtmauer
Bone Disease in Multiple Myeloma
Dr. Brian Durie
IMF Advocacy
Greg Brozeit with Christine Murphy and Arin Assero
Multiple Myeloma: Relapsed Disease
Dr. Sagar Lonial
Nutritional and Lifestyle Influences on Multiple Myeloma
Common Symptoms Of Multiple Myeloma
Fly A Virtual Kite and support the IMF!
Dr. Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota
More than 50 scientists were interviewed at this year's meeting of the American Society of Hematology (ASH)
Update from ASH 2009
The Role of Transplant
Update from ASH 2009
Treating Elderly Patients
Update from ASH 2009
Treating Younger Patients
4-? ??????????? ??????????? ???? ? ??????
ASH 2009: Edward Agura
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study
ASH 2009: Irene Ghobrial
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Don Benson
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
Update from ASH 2009:
Sequential Use of Treatments vs. Combinations
Update from ASH 2009:
Novel Agents
ASH 2009: Herv? Avet Loiseau
Induction with Velcade?/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma
ASH 2009
Herv? Avet Loiseau Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment
Neues vom ASH Kongress 2009
Una visione d?insieme dell?ASH 2009: Antonio Palumbo
ASH 2009 G?ncel ?zet
Un resumen de las presentaciones de ASH 2009
????? ??? 2009
Update From ASH 2009: Sequential Use Of Treatments vs.Combinations
ASH 2009: Sophie L. Corthals
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
ASH 2009: Pieter Sonneveld
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
ASH 2009: Sophie L. Corthals
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
ASH2009: Bank On A Cure? Update
ASH 2009: Gareth Morgan
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
ASH 2009: Gareth Morgan
The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS
ASH 2009: Ruben Niesvizky
Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Gareth Morgan, Bank On A Cure^®
ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
ASH 2009: Brian Durie
Bank On A Cure®
ASH 2009: Joan Blad?
Thalidomide/Dexamethasone (TD) Vs. Bortezomib (Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial
ASH 2009: Paul Richardson, Dana Farber Cancer Institute, Boston, Massachusetts
ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study
ASH 2009: Paul Richardson
Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model
ASH 2009: Jean-Luc Harousseau
High Complete and Very Good Partial Response Rates with Bortezomib?Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial
ASH 2009: Paul Richardson
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
ASH 2009: Paul Richardson
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
ASH 2009: Paul Richardson
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)
ASH 2009: Heinz Ludwig
Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
ASH 2009: Heinz Ludwig
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
Nouvelles d'ASH 2009
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Francesca Gay
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Jean-Luc Harousseau
Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin?], lenalidomide/[Revlimid?], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: David Siegel
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study
ASH 2009: David Siegel
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
ASH 2009: Sagar Lonial
Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone
ASH 2009: Sagar Lonial
Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
ASH 2009: Eric Sanchez
Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib
Myeloma Today - February 2002
ASH 2009: Heinz Ludwig
Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study
ASH 2009: Paul Richardson
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Sagar Lonial
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
ASH 2009: Morie Gertz, Stem Cell Transplant in Multiple Myeloma: Impact of Response Failure in the Era of Novel Therapies
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: Evangelos Terpos
High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment
ASH 2009: Sundar Jagannath
The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Jes?s San Miguel
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II ?Bologna 2002? Study
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
ASH 2009: Meral Beksac
Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group
ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Antonio Palumbo
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
ASH 2009: Sundar Jagannath, Overview
ASH 2009: Antonio Palumbo
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
ASH 2009: Martin Ellis
Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity
ASH 2009: Nina Shah
Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma
ASH 2009: Herve Avet-Loiseau
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
ASH 2009: Hayley Knollman, Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
IMF OFFICE HOLIDAY HOURS
ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
ASH 2009: Shaji Kumar
Novel Three? and Four?Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
ASH 2009: Shaji Kumar
Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID?s in Relapsed-Refractory Multiple Myeloma Patients
ASH 2009: Joseph R. Mikhael
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma
ASH 2009: Kai Neben
Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASH 2009: Maria-Victoria Mateos
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis
ASH 2009: Shaji Kumar
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation
ASH 2009: Masood Shammas
Evolution of Genomic Changes and Their Significance in Myeloma
ASH 2009: Choon Kee Lee
An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide
ASH 2009: Maria-Victoria Mateos
Bortezomib Plus Melphalan?Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan?Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years? Follow-up and Extensive Subsequent Therapy Use
ASH 2009: Mariateresa Fulciniti
Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma
ASH 2009: Nilanjan Ghosh
Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Vincent Rajkumar, Current Approaches To Treatment Of Myeloma
Advocacy Update - December 17, 2009
Advocacy Update: November 5, 2009
Myeloma Minute
January 7, 2010
Myeloma Minute
February 11, 2009
Myeloma Minute
January 26, 2009
Myeloma Minute
February 5, 2009
Myeloma Minute
June 5, 2009
Myeloma Minute
February 25, 2009
Myeloma Minute
March 1, 2009
Myeloma Minute
March 22, 2009
Myeloma Minute
April 5, 2009
Myeloma Minute
April 6, 2009
Myeloma Minute
July 7, 2009
Myeloma Minute
November 22, 2009
Myeloma Minute
December 17, 2008
VELCADE® Adds Long-Term Overall Survival Benefit to Label
ASH 2009: Maria-Victoria Mateos
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years
Eastern Cooperative Oncology Group - Guide To Clinical Trials
Gu?a de Ensayos Cl?n?cos para pac?entes con C?ncer
Public Policy Web Resources
Myeloma Today Spring 2009 in PDF
Myeloma Today Fall/Winter 2009/2010 + Special Gala Supplement
Revlimid - Perspectivas del Paciente
Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma
IMWG Guidelines for the Use of Bisphosphonates in Myeloma
Issues of importance to patients are getting lost in partisan battles in Congress. Get involved!
Mesenchymal cell cytotherapy for multiple myeloma
Mozobil Tip Card
The International Myeloma Foundation Welcomes Entertainment Industry Executive Amy Weiss to Board of Directors
Myeloma Today Summer 2009
Advocacy Staff
Advocacy Update - August 31, 2010
Research
About the Action Network
Prevention
Innovation
Equality of Access
Early Approval - National policies and procedures for early approval of new treatments need to be reformed and streamlined.
Experimental Therapies - A mechanism is needed to permit access to unapproved and experimental therapies for patients who have exhausted other available possibilities.
Advocacy Toolkit
Myeloma Advocacy Update - January 31, 2010
Characterization and preclinical evaluation of NKT cells in multiple myeloma
Reolysin: a novel reovirus-based therapy for multiple myeloma
Bone marrow microenvironment and multiple myeloma chemotherapy optimization
MMSET and epigenetic control in t(4;14) myelomas
Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins
Mensajero del Mieloma - Invierno 2009
Parte 1
Mensajero del Mieloma - Invierno 2009
Parte 2
Requesting your help with a Bone Health Survey for Myeloma Patients and Caregivers
IMWG Criteria for the Diagnosis of Myeloma and Guidelines for the Diagnostic Work-Up of Myeloma
IMF Call Me Now Service
Introduction
Dr. Brian G. M. Durie
The Evolving Role of Diagnostic Testing and Response Criteria
Dr. S. Vincent Rajkumar
Evidence-Based Approaches for Transplantation-Eligible Patients
Dr. Philippe Moreau
Practical Recommendations for Myeloma Patients Ineligible for Transplantation
Dr. Mario Boccadoro
New Approaches for Patients with Relapsed or Refractory Disease
Dr. Robert Z. Orlowski
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
What is Smoldering Myeloma?
IMWG consensus statement on the role of vertebral augmentation in multiple myeloma
IMF Welcomes Daniel Navid as Senior Global Analyst
Myeloma Awareness Month 2010
Support
Myeloma Awareness Month 2010
Education
Myeloma Awareness Month 2010
Research
Myeloma Awareness Month 2010
Advocacy
Special Gala Report - IMF 3rd Annual Comedy Celebration
Myeloma Today Spring 2010
Myeloma Minute
April 14, 2010
Myeloma Minute
April 1, 2010
Gruppo di Supporto
Question for the Hotline? Use Click to Talk!
Click to Talk
testing ifbyphone link
IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
Living Well with Multiple Myeloma teleconference series concludes November 19th with Hope, Stress, Myeloma & The Holidays.
Dr. Cavo - Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study
Advocacy Update - August 15, 2011
Myeloma Minute
April 30, 2010
Myeloma Advocacy Update - May 3, 2010
It's tonight! Michael McKean plays for the IMF in the final million dollar round of "JEOPARDY!"
INTERNATIONAL MYELOMA FOUNDATION OVERWHELMED AS CELEBRITY MICHAEL McKEAN WINS $1 MILLION GRAND PRIZE ON 'JEOPARDY!' MILLION DOLLAR CELEBRITY INVITATIONAL
RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Osteonecrosis of the Jaw and Biphosphonates
A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement
ESAs not the culprit: More studies required
Eliminating the complete response penalty from myeloma response criteria
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Watch Michael McKean Defend his Celebrity Jeopardy! Winnings on Jimmy Kimmel Live!
Clinically relevant end points and new drug approvals for myeloma
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
ASH 2009 Highlights for Patients with Myeloma
The IMF mourns the loss of Dr. Gregory Mundy, member of IMF Board of Scientific Advisors and Board of Directors.
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
Slide Set from the 2010 ONS Annual Congress Satellite Symposium
Changing Patient Care in Multiple Myeloma: The IMF Nurse Leadership Board?s Long-Term Survivorship Care Plan
Slide Set from the 2010 ONS Annual Congress Satellite Symposium
Changing Patient Care in Multiple Myeloma: The IMF Nurse Leadership Board?s Long-Term Survivorship Care Plan
Slide Set from the 2010 ONS Annual Congress Satellite Symposium
Changing Patient Care in Multiple Myeloma: The IMF Nurse Leadership Board?s Long-Term Survivorship Care Plan
Myeloma Today Fall 2010 in PDF format
The Hope Society
Targeting IRE1α-XBP1 pathway is a novel therapeutic strategy in multiple myeloma
Myeloma Minute
May 17, 2010
Advocacy Update - May 31, 2010
ASCO Presentations Point to Longer Remissions, Fewer Transplants and Implications Beyond Myeloma
First Anniversary Of "Cancer Patient Statement Of Principles" Marks Initial Progress On Reimbursement Parity For Oral Cancer Drugs
ASCO 2010: Overview
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
Michael and Robin Tuohy of Connecticut Help to Pass State Oral Parity Bill
ASCO 2010: Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study.
ASCO 2010: Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
IMF supports legislation to require equitable insurance reimbursement for oral cancer drugs
Advocacy Update - June 30, 2010
Virginia Support Group Leader Takes on Capitol Hill
Eighth Robert A. Kyle Lifetime Achievement Award presented to Dr. Joan Bladé
Advocacy Update - June 21, 2010
Myeloma Today Summer 2010
International Myeloma Working Group (IMWG) Molecular Classification of Multiple Myeloma
International Myeloma Working Group (IMWG) Guidelines for Serum Free Light Chain Analysis in Multiple Myeloma and Related Disorders
PX-171-009 – Phase III study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma (US)
Advocacy Update - July 15, 2010
Myeloma Minute
June 15, 2010
Myeloma Minute
June 29, 2010
Myeloma Minute
July 19, 2010
A Note from Michael McKean: "I?m a little overwhelmed by your gratitude."
The Power of Advocacy
4TH ANNUAL COMEDY CELEBRATION
4TH ANNUAL COMEDY CELEBRATION
EVENT SPONSORS
4TH ANNUAL COMEDY CELEBRATION
TICKETS & PRICING
4TH ANNUAL COMEDY CELEBRATION
SPONSORSHIPS & ADVERTISING
The International Myeloma Foundation Says Study Suggests Carfilzomib Could be Important New Treatment Option for Relapsed Myeloma Patients
Myeloma Minute
August 4, 2010
4TH ANNUAL COMEDY CELEBRATION SPONSORS
4TH ANNUAL COMEDY CELEBRATION HONORARY COMMITTEE
4TH ANNUAL COMEDY CELEBRATION TICKETS
4TH ANNUAL COMEDY CELEBRATION SPONSORSHIP & ADVERTISING OPPORTUNITIES
4TH ANNUAL COMEDY CELEBRATION PRESS/MEDIA
Nurse Leaders within the International Myeloma Foundation Publish Book for Nurses to Help Myeloma Patients Optimize Their Care
BEAT CANCER TO THE FINISH LINE
Living Well with Multiple Myeloma Teleconference - Nutrition
Advocacy Update
August 5, 2010
Advocacy Update - August 17, 2010
Myeloma Minute
August 18, 2010
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
Advice from an Advocate
California Senate Bill 961, which would require insurance companies to cover orally administered cancer treatments at the same rate as IV treatments has passed through the legislature!!
Myeloma Minute
September 2, 2010
THE INTERNATIONAL MYELOMA FOUNDATION ANNOUNCES BREAKTHROUGH AGREEMENT WITH CHINA TO SUPPORT MYELOMA TREATMENT, INFORMATION AND RESEARCH
GREAT NEWS!! "Survivor" makes semi-final round of the Sponsafier NASCAR design contest!
Advocacy Update - September 15, 2010
California Support Group Leader?s Testimony Makes Huge Difference
4th Annual Comedy Celebration Journal Specifications and Submission Requirements
4th Annual IMF Comedy Celebration Sponsorship Opportunities
David's 20th Anniversary Message
Advocacy Update - September 30, 2010
TWO MORE DAYS TO VOTE! Keep Voting for "The Survivor" to Beat Myeloma to the Finish!
Myeloma Minute
October 12, 2010
A.C.E. Levels
Training Overview PPT
The Importance of Voting on November 2nd
Thank you for your support of the Myeloma Survivor!
Case Studies in the Management of Venous Thromboembolic Events and Peripheral Neuropathy in Multiple Myeloma
Action Center Tutorial
Advocacy Update - October 15, 2010
IMF Advocates Make a Difference at OVAC Lobby Day
Advocacy 101 / HR 2746
PX-171-009 – Phase III study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma (Outside US)
Advocacy Update - November 15, 2010
New! Survey of your experience in obtaining access to the cancer medications recommended by your physician.
Living Well with Myeloma Teleconference - Hope, Stress, Myeloma & The Holidays
Everyone Makes a Difference!
Consensus on Care:Updates in the Management of Side Effects in Multiple Myeloma: A Case-Based Approach to Care
IMF Satellite Symposium: Key Myeloma Questions for 2010
Evolving Treatment Approaches in Transplantation-Eligible Myeloma Patients
IMF Satellite Symposium: Key Myeloma Questions for 2010
Emerging Therapies for Transplantation-Ineligible Patients With Myeloma
IMF Satellite Symposium: Key Myeloma Questions for 2010
Consolidation and Maintenance in Newly Diagnosed Symptomatic Multiple Myeloma
IMF Satellite Symposium: Key Myeloma Questions for 2010
Novel Agents and Regimens for Relapsed and Refractory Multiple Myeloma
The IMF Invites advocates in Wisconsin to Attend the 2011 Wisconsin ?Day at the Capitol?
Wednesday, March 2, 2011 10:00 a.m. ? 4:30 p.m.

COMING SOON! MyrooM! Home of the IMF blogs.
IMF is Proud to Announce a Cooperative Agreement with the Chinese Health Promotion Foundation
Myeloma Minute
November 29, 2010
Myeloma Minute
October 26, 2010
Advocacy Update - November 30, 2010
Dr. Lacy - Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease
ASH 2010 Overview from Dr. Kenneth Anderson
Dr. Niesvizky - Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients
Dr. Niesvizky - A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Dr. McCarthy - Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104
Dr. Niesvizky - Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin?], lenalidomide/[Revlimid?], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma
Dr. Siegel - Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
Dr. Gertz - Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization
Dr. Gertz - Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients
Dr. Morgan - Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial
Dr. Kaufman - Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study
Dr. Tricot - Targeting Myeloma Stem Cells through Simultaneous Inhibition of Wnt and Hedgehog (Hh) Signaling Pathways
Dr. Barlogie's Overview of ASH 2010
Why Should I Attend an IMF Patient Family Seminar?
Michael Tuohy
The Myeloma Patient's Guide to Understanding Your Test Results
Dr. Matsui - Origin of the Myeloma Stem Cell
Dr. Dunavin - Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma
Dr. Knop - The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma ? First Results of a Phase II Trial by the German DSMM Group
Dr. Vij - Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients
Dr. Zamagni - Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study
Dr. Richardson - A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Dr. Richardson - Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
Dr. Richardson - A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population
Dr. Richardson - Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up
Dr. Dimopoulos - Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years
Dr. Dimopoulos - Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma
Dr. Dimopoulos - Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study
Dr. Vesole - Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)
Dr. Vesole - Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study
Dr. Ghobrial - Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Dr. Ghobrial - Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma
Dr. Goldschmidt - Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis of the HOVON-65/GMMG-HD4 Trial
Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma
First Results of a Phase-II Study with the New CXCR4 Antagonist POL6326 to Mobilize Hematopoietic Stem Cells (HSC) In Multiple Myeloma (MM)
Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination
Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Dr. Siegel - Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial
Dr. Raje - Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study
Dr. Siegel - Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone
Dr. Jakubowiak - Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial
Dr. Raje - Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis
Dr. Jakubowiak - Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
The International Myeloma Foundation, Marking 20 Years of Serving the Myeloma Community, Applauds, Members of the International Myeloma Working Group for Their Body of Work Being Presented at the ASH Hematology Conference
Dr. Morgan - Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results
Advocacy Update - December 15, 2010
First Teleconference of 2011
Best of ASH ? What Patients Need to Know
Charitable IRA Rollover Extended for 2010 and 2011
????? ??? 2010
Dr. Zamagni - Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients
Dr. Van Ness - Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods
Dr. Stewart - A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial
Dr. Krishnan - Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial
Welcome to the International Myeloma Foundation's Blogs
Dr. Kumar - Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
Myeloma Today Winter 2010
Dr. Suvannasankha - Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM
Dr. Suvannasankha - Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
Dr. Lonial - Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Dr. Jagannath - Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Dr. Martin - Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)
Dr. Dispenzieri - A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis
Dr. Leleu - MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients with Multiple Myeloma Treated with Immunomodulator Drugs
Advocate Writes to Make a Difference
Dr. Kumar - Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma
Dr. Kumar - Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma
A survey about Erythropoiesis Stimulating Agents (ESAs) is being conducted. You can take it online or by phone.
Dr. Bladé - Un resumen de las presentaciones de ASH 2010
Dr. Ludwig - The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress 2010
Dr. Cavo - Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
Dr. Sezer - Ein ?berblick ?ber den ASH-Kongress 2010
Dr. Sezer - ASH 2010 G?ncel ?zet
Dr. San Miguel- Un resumen de las presentaciones de ASH 2010
Dr. Waage - En oversikt over ASH 2010
Advocacy Update - January 20, 2011
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Welcome and Introductions
Update on Current Therapies for the Treatment of Multiple Myeloma
The NLB's Long-Term Survivorship Care Plan
Impact of Myeloma Disease, Treatments, Long-Term Effects, and Patient-Specific Characteristics on Bone Disease and Bone Health, Functional Mobility and Safety
Dr. Palumbo - A Phase III Study Evaluating the Efficacy and Safety of Lenalidomide Combined With Melphalan and Prednisone in Patients ? 65 Years With Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide vs Fixed-Duration Regimens
Dr. Palumbo - Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors
Advocacy Update - January 31, 2011
IMF Advocates Take Huge Step toward Change in Wisconsin
Impact of Myeloma Disease, Treatments, Long-Term Effects, and Patient-Specific Characteristics on Renal Complications, Sexuality and Sexual Dysfunction
Impact of Myeloma Disease, Treatments, Long-Term Effects, and Patient-Specific Characteristics on Health Maintenance
Dr. Sher - Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
Dr. Sher - Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination
Inaugural Meeting of the International Myeloma Foundation Asian Myeloma Network (AMN)
Friends Program 2011
Frequently Asked Questions
February 13, 2011: Second Primary Cancers (SPCs)
Advocacy Update - February 15, 2011
Follow-up Statement from Support Group Leader Conference Call on Second Primary Cancers
An update on the management of the side effects of myeloma and novel agents.
March 3rd
Sign up TODAY for Advocacy Training Two-Part Online Series!
Myeloma Awareness Month 2011 – Clinical Trials: Why they're important and why you should consider participating in one.
March 10th
Messager de Myélome
Myeloma Awareness Month 2011 ? Making Sense of Medicare.
March 24th
Rationally Designed Pralatrexate Combination Therapies for MM
Myeloma Awareness Month 2011 ? Living with Myeloma: The Psychosocial Issues.
March 31th
Metabolic-targeting Therapy for Multiple Myeloma
MMSET and epigenetic control in t(4;14) myelomas
2nd Year Funding
Targeting the Translational Machinery in Multiple Myeloma
Epigenetics in multiple myeloma and prospects for translational research
The Role of Histone Deacetylases in Drug Resistance of Multiple Myeloma Cells
Catch Me If You Can
Special IMF Benefit Performance
Friday, April 8, 2011 at 8pm
Advocacy Update - February 28, 2011
The Behind-the-Scenes Advocate
NLB Teleconference - Updates in the Management of Myeloma: New Treatments on the Horizon
MYELOMA TODAY – Special Gala Report
1000 CRANES OF HOPE
For every Crane created during the months of March, April and May, Millennium will make a donation to the IMF.
Myelom Merkur - September 2009
Nouvelle édition! Messager de My?lome
Advocacy Update - March 15, 2011
Dr. Abildgaard - Updates from Haematological Research Unit at University of Southern Denmark
??? ???????? ???????? - ???????, ???????
Advocacy Update
Myelom Merkur - Juni 2009
Myelom Merkur - Mai 2010
Myelom Merkur - Juni 2010
IMF NOTES PASSING OF GERALDINE FERRARO, PIONEERING POLITICIAN
Myelom Merkur - October 2010
Advocate?s Testimony in New Mexico Helps Pass Important Legislation
Advocacy Update - March 31, 2011
Nurses! Register now for IMF?s NLB Satellite Symposium at the 36th Annual ONS Congress.
IMF Helps with Big Win for Cancer Patients in New Mexico: Advocate's moving testimony helps with passage of Oral Drug Parity Bill.
Myeloma Today Spring 2011
ASH 2010 Multiple Myeloma Highlights for Physicians
Nuova Edizione! Il Messaggero di Mieloma
Salvatore L. Ruggiero, DMD, MD Talks About Osteonecrosis of the Jaw (ONJ)
Cancer Patients, Families, and Supporters Gather for Annual "Miles for Myeloma"
ASH 2010 Highlights for Patients with Myeloma
What Does the IMF Do For You?
Boca Raton 2011 Patient & Family Seminar
Dr. Gertz - Myeloma 101
Boca Raton 2011 Patient & Family Seminar
Dr. Kyle - Best Therapies for Elderly Patients
Boca Raton 2011 Patient & Family Seminar
Dr. Barlogie - Cure of Myeloma; A Personal Odyssey
Boca Raton 2011 Patient & Family Seminar
Dr. Durie - Management of Bone Disease
Boca Raton 2011 Patient & Family Seminar
Dr. Boccadoro - Update on European Clinical Trials
Boca Raton 2011 Patient & Family Seminar
Advocacy Update - April 15, 2011
Dr. Anderson - Clinical Trials and New Drugs
Boca Raton 2011 Patient & Family Seminar
Douglas E. Joshua, AM
Advocacy Update - April 30, 2011
International Myeloma Workshop 2011
Dr. Fonseca - MOLECULAR PATHWAYS/GENETICS SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Klein - PLASMA CELL BIOLOGY SESSION SUMMARY
International Myeloma Workshop 2011
OPENING REMARKS
International Myeloma Workshop 2011
Dr. Stewart - HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT SESSION SUMMARY
?A Day at the Capitol? ? Wisconsin Lobby Day
International Myeloma Workshop 2011
MOLECULAR PATHWAYS/GENETICS Dr. Avet-Loiseau - Introduction
International Myeloma Workshop 2011
MOLECULAR PATHWAYS/GENETICS
Dr. Fonseca - The Different Subtypes of Myeloma
International Myeloma Workshop 2011
MOLECULAR PATHWAYS/GENETICS
Panel Discussion
International Myeloma Workshop 2011
MOLECULAR PATHWAYS/GENETICS
Dr. Minvielle - The Genetic Progression of Myeloma
International Myeloma Workshop 2011
PLASMA CELL BIOLOGY
Dr. Lee - Introduction lecture: "The UPR system"
Update from IMW 2011: Histone Deacetylase (HDAC) Inhibitors
Drs. Anderson and Lonial
Update from IMW 2011: Immunomodulators (IMiDs)
Dr. Kenneth Anderson
Update from IMW 2011: Proteasome Inhibitors
Dr. Kenneth Anderson
The International Myeloma Foundation : Study Says Long-Term Maintenance Treatment Demonstrates 90% Overall Survival Rate
International Myeloma Workshop 2011
Dr. Mateos - HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Merlini - MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
International Myeloma Workshop 2011
Dr. Morgan - HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT SESSION SUMMARY
International Myeloma Workshop 2011
Dr.Lonial - DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM? SESSION SUMMARY
International Myeloma Workshop 2011
Dr.Palumbo - NEWLY DIAGNOSED MYELOMA>65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
International Myeloma Workshop 2011
Dr.Landgren - SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE? SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Boccadoro - NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Merlini - MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Mateos - NEWLY DIAGNOSED MYELOMA >65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
International Myeloma Workshop 2011
MOLECULAR PATHWAYS/GENETICS
Dr. Croce - Introduction Lecture: Physiopathology of Myeloma. What Role for MicroRNAs?
International Myeloma Workshop 2011
PLASMA CELL BIOLOGY
Dr. Klein - Cytokine Pathways: Which One to Target?
International Myeloma Workshop 2011
PLASMA CELL BIOLOGY
Dr. Lichtenstein - mTOR Complex Pathway in Myeloma
International Myeloma Workshop 2011
MOLECULAR PATHWAYS/GENETICS
Dr. Avet-Loiseau - Introduction
International Myeloma Workshop 2011
PLASMA CELL BIOLOGY
Panel discussion
International Myeloma Workshop 2011
PLASMA CELL BIOLOGY
Dr. Sanderson - Heparanase and Syndecan-1: Promoters of Aggressive Myeloma Behaviour and Targets for Therapy
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Dr. Roodman - Introduction Lecture: "Bone disease: From Physiopathology to Treatment"
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Dr. Yaccoby - Bone Anabolism and Tumor Growth in Myeloma
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Dr. Giuliani - Effect of New Anti-myeloma Drugs on Bone Microenvironment Cells
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Dr. Ayati - Mathematical Descriptions of Bone Remodeling Dynamics
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Dr. Tassone - Dissecting the Multiple Myeloma Tumor Microenvironment: A Novel In Vivo Platform
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Dr. Vanderkerken - Epigenetic Changes of Myeloma Cells Within the Bone Marrow Microenvironment
International Myeloma Workshop 2011
BONE DISEASE AND ANIMAL MODELS
Panel Discussion
International Myeloma Workshop 2011
Dr. Raje - PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Terpos - PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE SESSION SUMMARY
International Myeloma Workshop 2011
Dr.Rajkumar - NEWLY DIAGNOSED MYELOMA >65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
International Myeloma Workshop 2011
Dr. Giuliani - BONE DISEASE AND ANIMAL MODELS SESSION SUMMARY
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Moreau - Report from IFM-DFCI
International Myeloma Workshop 2011
Dr.Jagannath - NEW DRUGS AND THERAPEUTIC APPROACHES SESSION SUMMARY
Update from IMW 2011: Monoclonal Antibodies
Dr. Sundar Jagannath
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Goldschmidt - Report from GMMG
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Cavo - Report from EMNTG-HOVON-GIMEMA
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Sonneveld - Report from EMNTG-HOVON-GIMEMA
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Barlogie - Report from Arkansas
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Barlogie - Report from Arkansas
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Morgan - Report from EMNTG-MRC
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Giralt - Report from CTN-BMT
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Panel Discussion
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Dr. Bergsagel - t(4&14) and Genomic Instability in High-Risk Myeloma
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Dr. Licht - The molecular biology of the MMSET protein of t(4-14) Myeloma
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Dr. Stewart - Whole Genome Sequencing in high-risk Myeloma
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Dr. Barlogie - What is GEP-defined high-risk Myeloma?
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Dr. Morgan - The implications of High-risk Myeloma to therapy
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Dr. Einsele - Allogeneic stem cell transplantation for high-risk Myeloma
International Myeloma Workshop 2011
HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT
Panel Discussion
International Myeloma Workshop 2011
DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM?
Dr. Gertz - Introduction to Debate
International Myeloma Workshop 2011
DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM?
Dr. Mateos - For Treatment
International Myeloma Workshop 2011
DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM?
Dr. Lonial - Against Treatment
International Myeloma Workshop 2011
DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM?
Panel Discussion
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Dr. Dimopoulos - Introduction lecture: "Bone imaging in Myeloma: old scaffolds and new avenues"
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Dr. Hillengass - Whole-body MRI in Myeloma
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Dr. Gimsing - Bisphosphonates: Can the Dose be Lowered?
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Dr. Child - Zoledronic Acid in the Management of Myeloma
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Dr. Raje - Osteonecrosis of the Jaw
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Dr. Terpos - Should we use markers of bone remodelling in Myeloma? Which one and when?
International Myeloma Workshop 2011
PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE
Panel Discussion
International Myeloma Workshop 2011
MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
Dr. Pepys - Introduction lecture: "Therapeutic elimination of amyloid deposits: is it possible?"
International Myeloma Workshop 2011
MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
Dr. Merlini - Management of AL amyloidosis in 2011
International Myeloma Workshop 2011
MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
Dr. Bridoux - Myeloma Cast Nephropathy
International Myeloma Workshop 2011
MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
Dr. Leung - Myeloma Cast Nephropathy
International Myeloma Workshop 2011
MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
Dr. Hutchison - Myeloma Cast Nephropathy
International Myeloma Workshop 2011
MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS
Panel Discussion
New book from Hardy Jones, ocean conservationist and myeloma patient, The Voice of the Dolphins.
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Rajkumar - How I treat a patient NOT eligible for high dose therapy and auto-transplantation?
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Palumbo - Report from EMNTG-GIMEMA
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Mateos - Report from EMNTG-Pethema/GEM
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Straka - Report from EMNTG-DSMM
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Weber - Report from US Intergroup
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Zweegman - Report from EMNTG-Hovon/Nordic
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Davies - Report from EMNTG-MRC
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Dr. Facon - Report from IFM
International Myeloma Workshop 2011
MYELOMA >65 YEARS NEWLY DIAGNOSED: FACTS & QUESTIONS
Panel Discussion
Advocacy Update - May 15, 2011
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Anderson - Introduction Lecture
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Spencer - Pre-clinical Evaluation and Identification of Novel Therapeutics
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Chauhan - Preclinical Basis for 2nd Generation Proteasome Inhibitors
Presented by Dr. Kenneth Anderson
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Jakubowiak - Carfilzomib and Other New Proteasome Inhibitors: Clinical data
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Lacy - Current Status of Pomalidomide in Myeloma
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Ocio - Histone Deacetylase Inhibitors
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Dr. Jagannath - Monoclonal Antibodies in the Treatment of Myeloma
International Myeloma Workshop 2011
NEW DRUGS AND THERAPEUTIC APPROACHES
Panel Discussion
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Dr. Fermand - Introduction
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Dr. Attal - Maintenance Treatment with Lenalidomide after Transplantation for Myeloma: Analysis of Secondary Malignancies within the IFM 2005-02 Trial
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Dr. McCarthy - Phase III Intergroup Study of Lenalidomide versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM): CALGB ECOG BMT-CNT 100104
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Dr. Palumbo - Secondary Malignancies in Elderly Myeloma Patients
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Dr. Morgan - Retrospective Analysis of the Long Term Safety of Lenalidomide ? Dexamethasone in Relapsed/Refractory Myeloma Patients: Analysis of Pooled Data and Incidence Rates of Second Primary Malignancy
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Dr. Landgren - Risk of Subsequent Primary Malignancies in Patients with Multiple Myeloma Before and After the Introduction of Novel Therapies: A Population-based Study in Sweden
International Myeloma Workshop 2011
SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE?
Panel Discussion
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Dr. Joshua - Immunotherapy in Myeloma: Myth or Reality?
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Dr. Lokhorst - Current Place of Allogeneic Transplantation in Myeloma
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Dr. Bae - Multiepitope Vaccine to Treat Patients with Myeloma-related Disease: Potential Clinical Application
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Dr. Sawyer - Jumping Translocations 1Q12 Contribute to Copy Number (CN) variations in Multiple Myeloma: Unexpected CN Gains Involving Duplications and Translocations of Receptor Chromosomes
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Dr. Zhu - Cereblon (CRBN) is a Requirement for the Anti-myeloma Activity of Thalidomide, Lenalidomide and Pomalidomide
Presented by Dr. Keith Stewart
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Dr. Trudel - Identification of GSK-3 as a Primary Target of imids and Biomarker of Clinical Response using Drosophila
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION I
Panel Discussion
International Myeloma Workshop 2011
MONOCLONAL IMMUNOGLOBULIN AND THE NERVE, WALDENSTROM'S MACROGLOBULINEMIA
Dr. Nobile-Orazio - Neuropathy in Monoclonal Gammopathy
International Myeloma Workshop 2011
MONOCLONAL IMMUNOGLOBULIN AND THE NERVE, WALDENSTROM'S MACROGLOBULINEMIA
Dr. Dispenzieri - Poems Syndrome
International Myeloma Workshop 2011
MONOCLONAL IMMUNOGLOBULIN AND THE NERVE, WALDENSTROM'S MACROGLOBULINEMIA
Dr. Treon - Update in the Treatment of WM
Myeloma Minute
May 24, 2011
International Myeloma Workshop 2011
CONSENSUS REPORT: Panel 1
Dr. Roodman - Consensus guidelines for the management of bone disease in multiple myeloma
International Myeloma Workshop 2011
CONSENSUS REPORT: Panel 2
Dr. Munshi - Consensus guidelines for diagnostic Criteria and Indication for treatment and retreatment in plasma cell disorders
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Futreal - INTRODUCTION LECTURE: Initial genome sequencing: a new step in understanding Myeloma?
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Cavallo - A Phase III Study of Enoxaparin vs Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-based Regimens
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Owen - Minimal residual disease (MRD) assessment using multiparameter flow cytometry (MFC) predicts outcome in both intensively and non-intensively treated patients: results from the MRC myeloma IX trial
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Zamagni - Prognostic relevance of 18F-FDG PET/CT in newly diagnosed Multiple Myeloma patients receiving up-front autologous stem-cell transplantation (ASCT): a prospective study
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Mellqvist - Improved progression free survival with bortezomib consolidation after high dose melphalan; results of a randomized phase III trial
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Richardson - A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose (MTD), safety, and efficacy of pomalidomide (POM) alone or in combination with low-dose dexamethasone (DEX) in patients (PTS) with relapsed and refractory Multiple Myeloma (RRMM) who have received prior treatment (TX) that includes lenalidomide (LEN) and bortezomib (BORT)
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Martin - Results of PX-171-003-A1, an open-label, single-arm, phase (PH) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed/refractory Multiple Myeloma (R/R MM)
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Libby - Declining myeloma mortality rates in the United States following introduction of novel therapies
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Panel Discussion
International Myeloma Workshop 2011
CONSENSUS REPORTS
Dr. Munshi - Introduction to the Consensus Panels and Their Reports
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Futreal - INTRODUCTION LECTURE: Initial genome sequencing: a new step in understanding Myeloma?
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Cavallo - A Phase III Study of Enoxaparin vs Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-based Regimens
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Owen - Minimal residual disease (MRD) assessment using multiparameter flow cytometry (MFC) predicts outcome in both intensively and non-intensively treated patients: results from the MRC myeloma IX trial
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Zamagni - Prognostic relevance of 18F-FDG PET/CT in newly diagnosed Multiple Myeloma patients receiving up-front autologous stem-cell transplantation (ASCT): a prospective study
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Mellqvist - Improved progression free survival with bortezomib consolidation after high dose melphalan; results of a randomized phase III trial
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Richardson - A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose (MTD), safety, and efficacy of pomalidomide (POM) alone or in combination with low-dose dexamethasone (DEX) in patients (PTS) with relapsed and refractory Multiple Myeloma (RRMM) who have received prior treatment (TX) that includes lenalidomide (LEN) and bortezomib (BORT)
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Martin - Results of PX-171-003-A1, an open-label, single-arm, phase (PH) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed/refractory Multiple Myeloma (R/R MM)
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Libby - Declining myeloma mortality rates in the United States following introduction of novel therapies
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Panel Discussion
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Cavo - How I treat a patient eligible for high dose therapy and auto-transplant?
International Myeloma Workshop 2011
NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS
Dr. Rosi?ol - Report from EMNTG-Pethema/GEM
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Futreal - INTRODUCTION LECTURE: Initial genome sequencing: a new step in understanding Myeloma?
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Cavallo - A Phase III Study of Enoxaparin vs Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-based Regimens
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Owen - Minimal residual disease (MRD) assessment using multiparameter flow cytometry (MFC) predicts outcome in both intensively and non-intensively treated patients: results from the MRC myeloma IX trial
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Zamagni - Prognostic relevance of 18F-FDG PET/CT in newly diagnosed Multiple Myeloma patients receiving up-front autologous stem-cell transplantation (ASCT): a prospective study
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Panel Discussion I
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Mellqvist - Improved progression free survival with bortezomib consolidation after high dose melphalan; results of a randomized phase III trial
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Richardson - A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory Multiple Myeloma who have received prior treatment that includes lenalidomide and bortezomib
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Siegel - Results of PX-171-003-A1, an open-label, single-arm, phase (PH) 2 study of carfilzomib in patients with relapsed/refractory Multiple Myeloma
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Libby - Declining myeloma mortality rates in the United States following introduction of novel therapies
International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Panel Discussion II
Myeloma Minute
March 24, 2011
One Voice Against Cancer (OVAC) Annual Lobby Day 2011
IMWG Consensus Statement Regarding the Current Status of Allogeneic Stem Cell Transplantation for Multiple Myeloma
Myeloma Today Summer 2011
Advocacy Update - June 15, 2011
Central New Jersey Support Group Leader?s Testimony Makes a Difference
Smoldering Myeloma (low risk)
Smoldering Myeloma (high risk)
Solitary Plasmacytoma of Bone
About the IMF
Long-Term Survivorship Guidelines for Multiple Myeloma Patients
The IMF NLB Survivorship Care Plan by Joseph Tariman, PhD, APRN, BC
Long-Term Survivorship Guidelines for Multiple Myeloma Patients
Kathleen Colson, RN, BSN, BS
Long-Term Survivorship Guidelines for Multiple Myeloma Patients
Elizabeth Bilotti, MSN, APRN, BC
STEP 9: RELAPSE - DO YOU NEED A CHANGE IN TREATMENT?
REFERENCES

STEP 3: INITIAL TREATMENT SELECTION - GETTING THE BEST TREATMENT
REFERENCES
STEP 6: RESPONSE ASSESSMENT - IS TREATMENT WORKING?
REFERENCES
Value of a Transplant
How to Decide If You Need a Transplant
Questions and Answers about Stem Cell Transplantation
Transplants and Clinical Trials
The Transplant Procedure

IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published in the Clinical Journal of Oncology Nursing.
Psychosocial Issues Surrounding Transplant
IMPORTANT PHILADELPHIA PATIENT & FAMILY SEMINAR UPDATE!
Living Well with Myeloma 2011 – Clinical Trials: Why they're important and why you should consider participating in one.
Monoclonal Gammopathy of Undetermined Significance (MGUS) References
STEP 2 - REFERENCES
STEP 5 - TRANSPLANT REFERENCES
IMF ????? ????? ?????? ?? ????? ? - Revlimid ?
IMF ????? ????? ?????? ?? ????? ? - Revlimid ?
,IMF????? ?? ????? ?? ??????? ????? ?"? ????? ??"?, ??????? ???????? ? ????? ???? ????? ??????? ?????? 3/6/2011 ????? ????? ???????. ????? ?? ???? ?? ??????? ?? ????? ??"?
Florida Advocate Seeks Support of HR 2746
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
THE 10 STEPS TO BETTER CARE
Advocacy Update - September 16, 2011
What is the International Myeloma Working Group?
Tennessee Support Group Leader Has Chance Meeting with Representative
New Teleconference from the Cancer Legal Resource Center! Cancer and Careers - October 13
"Update on Novel Therapies" Teleconference with Bonnie Jenkins, RN
Originally aired on October 20, 2011.
Important DOXIL Update!
Myeloma Today Fall 2011
What is the Immunoglobulin Free Light Chain Assay and How is It Used?
Advocacy Update - October 15, 2011
On Your Marks, Get Set, BID! Bid on all items available during the silent auction at the 5th Annual Comedy Celebration without having to get out of your pajamas!
10 STEPS TO BETTER CARE^™
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
New Jersey Advocate Persuades Representative to Co-Sponsor HR 2746
Myeloma Canada Announces Recipient of this Year?s Research Grant
Pomalidomide + carfilzomib trial to open.
2011 IMF Holiday Gift Boutique
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
Understanding Mozobil^® (plerixafor injection)
STEP 10: NEW TRIALS: HOW TO FIND THEM - REFERENCES
Advocacy Update - November 15, 2011
ASH 2011: Dr. Kapoor - Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies
ASH 2011: Dr. Adel - Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC)
Dr. Anderson - An Overview of ASH 2011
ASH 2011: Dr. Avet-Loiseau - Incidence and Prognostic Value of Chromosomal Abnormalities in Elderly Patients with myeloma: The IFM Experience on 1095 Patients
ASH 2011: Dr. Bang - Treatment Patterns and Outcomes in Elderly Patients with Multiple Myeloma
Dr. Barlogie - An Overview of ASH 2011
ASH 2011: Dr. Beksa? - G?ncel ?zet
ASH 2011: Dr. Beksa? - Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups
??? ???????? ????????? - ?? ?????, ?????????
ASH 2011: Dr. Berdeja - Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
ASH 2011: Dr. Berenson - Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
ASH 2011: Dr. Bruno - Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry
ASH 2011: Dr. Dimopoulos - Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
ASH 2011: Dr. Dimopoulos - Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial
ASH 2011: Dr. Dimopoulos - The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients
ASH 2011: Dr. Harvey - Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
Dr. Durie - An Overview of ASH 2011
ASH 2011: Dr. Fenk - Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation
ASH 2011: Dr. Fern?ndez de Larrea - Impact of Global and Gene-Specific DNA Methylation Pattern in Relapsed Multiple Myeloma Patients Treated with Bortezomib
Dr. Gertz: An Overview of ASH 2011
More Advocates Take Action on HR 2746!
Recording of Live Stream of Myeloma Questions and Controversies: New Developments in 2011 That Impact Diagnosis, Prognosis, and Treatment
Introduce Yourself to Multiple Myeloma and the IMF with the Tip Card
Webcast of the IMF Journalists? Workshop from ASH 2011 on 12/12/11
ASH 2011: Daniel Heintel - High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone
ASH 2011: Dr. Hillengass - Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation
ASH 2011: Dr. Jagannath - BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2011: Dr. Jagannath - Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study
ASH 2011: Dr. Jakubowiak - Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)
ASH 2011: Martina Kleber - Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients
ASH 2011: Dr. Kumar - Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
ASH 2011: Dr. Kumar - Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia
ASH 2011: Dr. Kumar - Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy
ASH 2011: Dr. Lacy - Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years.
ASH 2011: Dr. Ladetto - Long-Term Results of the GIMEMA VTD Consolidation Trial In Autografted Multiple Myeloma Patients (VEL-03-096): Impact of Minimal Residual Disease Detection by Real Time Quantitative PCR On Late Recurrences and Overall Survival.
ASH 2011: Dr. Leleu - Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs
ASH 2011: Dr. Leleu - High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02
ASH 2011: Dr. Lentzsch - Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study
ASH 2011: Dr. Lonial - The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
ASH 2011: Dr. Lonial - A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
ASH 2011: Dr. L?pez Corral - SNP-Based Mapping Arrays Reveal High Genomic Complexity in Monoclonal Gammopathies: From the MGUS to Myeloma Status
ASH 2011: Dr. Ludwig - Serum Heavy/Light Chain and Free Light Chain Measurements Provide Prognostic Information, Allow Creation of a Prognostic Model and Identify Clonal Changes (clonal tiding) Through the Course of Multiple Myeloma (MM).
ASH 2011: Dr. Ludwig - Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians
ASH 2011: Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress 2011
ASH 2011: Roberto Magalhaes - Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control
ASH 2011: Dr. Mark - T-Bird (thalidomide, clarithromycin/[Biaxin?], lenalidomide/[Revlimid?], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma
ASH 2011: Dr. Mark - A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma
ASH 2011: Dr. Mark - ClaPD (Clarithromycin/[Biaxin?], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
ASH 2011: Dr. Mateos - Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial
ASH 2011: Dr. Mikhael - Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort
ASH 2011: Dr. Monaghan - Longitudinal Evaluation of 110 Bone Marrow Aspirates of Multiple Myeloma Patients Treated with Lenalidomide Alone or in Combination with Autologous Stem Cell Transplantation or Alkylators for Early Dysplastic Signs
ASH 2011: Dr. Moreau - Nouvelles d'ASH 2011
ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
ASH 2011: Dr. Morgan - MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease
ASH 2011: Dr. Munshi - Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
ASH 2011: Pellegrino Musto - Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia
ASH 2011: Dr. Neben - Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial
ASH 2011: Dr. Niesvizky - Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study
ASH 2011: Dr. Niesvizky - Preliminary Results of a Phase I/II Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
ASH 2011: Dr. Nooka - Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
ASH 2011: Dr. Nooka - The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
ASH 2011: Dr. Ocio - Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM
ASH 2011: Dr. Paiva - High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)
ASH 2011: Dr. Palumbo - Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients
ASH 2011: Dr. Palumbo - Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study
ASH 2011: Dr. Palumbo - A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ? 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015
ASH 2011: Dr. Palumbo - A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
ASH 2011: Dr. Palumbo - Una visione d?insieme dell?ASH 2011
ASH 2011: Dr. Popat - An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy
Dr. Rajkumar - An Overview of ASH 2011
ASH 2011: Vishal Rana - Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma
ASH 2011: Dr. Richardson - Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
ASH 2011: Dr. Richardson - Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
ASH 2011: Dr. Richardson - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
ASH 2011: Dr. Richardson - Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
ASH 2011: Murielle Roussel - Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program
ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)
ASH 2011: Dr. San Miguel - Continued Overall Survival Benefit After 5 Years? Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
ASH 2011: Dr. Siegel - Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
ASH 2011: Dr. Sonneveld - Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN
ASH 2011: Dr Terragna - A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
ASH 2011: Dr. Usmani - Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases
ASH 2011: Dr. Usmani - Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol
ASH 2011: Dr. Usmani - Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3
ASH 2011: Dr. Vij - Final Results From the Bortezomib-na?ve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
ASH 2011: Dr. Zamagni - Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications
ASH 2011: Dr. Zhu - Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide
ASH 2011: Dr. Zingone - Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study
10 Years after Introduction of the Novel Therapies Survival, Quality of Life, and Treatment Options Significantly Improve
Best of ASH 2011 ? What Patients Need to Know
Special Myeloma Minute on FDA Approved Data for VELCADE?, including long-term survival data
ASH 2011 Highlights
Advocacy Update - January 16, 2012
Amen Newsletters
Advocacy Update - December 19, 2011
Myeloma Today Winter 2011
Nurse Leadership Board Member Makes a Difference in New Jersey
Rational Design of Heparanase Inhibiting Compounds and Antibodies for the Treatment of Multiple Myeloma
The Role of C/EBPbeta as a Potential Novel Target for the Treatment of Multiple Myeloma
Identification of Gene Networks Regulated by Glucocorticoids in Myeloma
Targeting UBC13-UEV1A for Treatment of Multiple Myeloma
Investigating the role of NAD+ and NAD+-dependent enzymes in Multiple Myeloma
GSK3beta Inhibition Reduces the Effects of Multiple Myeloma Induced Bone Disease
Specific Inhibitors of Ubiquitin-Dependent Proteasomal Degradation
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Delaware Support Group Leader Makes Huge Impact at Press Conference in Delaware
IMWG Guidelines for the Management of Treatment-Emergent Peripheral Neuropathy in Multiple Myeloma (MM)